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ABSTRACT

Author: Pei, Yihua. PhD
Institution: Purdue University
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Title: Particle Engineering for Intracellular Delivery of Antibiotics
Committee Chair: Yoon Yeo
Infections by intracellular bacteria have been recognized for many years, but they are
difficult to cure due to the poor intracellular penetration of most antibiotics. To overcome poor
intracellular delivery of antibiotics, we developed two polymeric nanoparticle formulation (NPs)
that efficiently encapsulate and deliver antibiotics to the target cells – the macrophages in the
liver and spleen. The first formulation (PpZEV) was based on a blend of polymers with distinct
functions: (i) poly(lactic-co-glycolic acid) (PLGA, P) serving as the main delivery platform, (ii)
polyethylene glycol-PLGA conjugate (PEG-PLGA, p) to help maintain an appropriate level of
polarity for timely release of vancomycin, (iii) Eudragit E100 (a copolymer based on
dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate, E) to enhance
vancomycin encapsulation, and (iv) a chitosan derivative called ZWC (Z) to trigger pH-sensitive
drug release. PpZEV NPs were preferentially taken up by the macrophages due to its size (5001000 nm) and facilitated vancomycin delivery to the intracellular pathogens. Accordingly,
PpZEV NPs showed better antimicrobial activity than free vancomycin against intracellular
MRSA both in vitro and in vivo. Additionally, we developed a novel particle engineering method
for encapsulating hydrophilic antibiotics in polymeric tannic acid nanocapsules. The hydrophilic
drugs are encapsulated via quasi-emulsion method modified from inversion emulsion
polymerization, using glycerol as the continuous phase instead of organic solvents. The method
is simple, low-cost and can achieve >10% drug loading (drug/NPs) in all tested antibiotics

xvii
(RRIKA, polymyxin B and vancomycin) in NPs with a size of 200 – 600 nm, a particle size
suitable for intracellular drug delivery to macrophages. These results indicates that both PpZEV
and pTA NPs are promising carriers for intracellular delivery of antibiotics.

1

INTRODUCTION

1.1

Introduction
Macrophages play various roles in mammalian biology, including development,

homeostasis, repair, and innate immunity [1]. Accordingly, macrophages have been an important
subject of drug delivery research. Macrophages are main hosts of intracellular pathogens in
chronic infectious diseases and, thus, pursued as a therapeutic target for intracellular delivery of
antibiotics. Moreover, macrophages have gained increasing interest as a therapeutic target for
cancer immunotherapy due to their complex roles in tumor microenvironment. Although
traditional drug delivery research has often viewed macrophages as an undesirable interceptor of
drug carriers, it is worthwhile to consider the biological roles of macrophages in a broader
therapeutic context and actively exploit them as a target for drug delivery. In this chapter, we
discuss various approaches to deliver drugs to macrophages in recent literature, their contribution
to therapeutic outcomes, and remaining challenges in macrophage-targeted drug delivery.

1.2

Biological roles of macrophages
The best-known source of tissue-resident macrophages is blood monocytes, derived from

hematopoietic stem cells in the bone marrow, which undergo several differentiation steps to
commit to a monocyte lineage [1] (Fig. 1a). Circulating monocytes are recruited to various
tissues and differentiated into macrophages according to the environmental cues [2, 3]. In
addition, recent studies find that tissue-resident macrophages may also be derived from
_____________________________________________

The content of this chapter is reprinted with permission from “Drug delivery to Drug delivery to macrophages:
Challenges and opportunities” by Pei, Y. and Yeo, Y., 2016. J Control Release, 240:202-21. Copyright (2015)
Elsevier.
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embryonic precursors, such as microglial cells from yolk sac and Langerhans cells from fetal
liver, and maintained by self-renewal [4]. Tissue-resident macrophages provide diverse functions
according to the anatomical locations. Kupffer cells in the liver are mainly involved in the waste
disposal process, such as clearance of microbes and cell debris from the blood [5]; alveolar
macrophages in the lungs serve as the first-line defender against the inhaled pathogens [6]; and
red pulp macrophages in the spleen are responsible for the removal of senescent erythrocytes and
iron flux regulation [7]. In addition to the reticuloendothelial system (RES), several other tissues
have resident macrophages with distinct functions, such as osteoclasts (mineral disruption) and
bone marrow macrophages (erythropoiesis support) in the bone, microglia cells (immune
surveillance) in the brain, intestinal macrophages (intestinal homeostasis maintenance) in the
gastrointestinal tract, and Langerhans cells (interaction with T lymphocytes) in the skin [5].
Macrophages may be categorized along a linear scale according to their activation status:
M1 macrophages (classically activated macrophages) on one extreme and M2 macrophages
(alternatively activated macrophages) on the other side (Fig. 1b) [1]. Activation into the M1
phenotype occurs via cellular or exogenous stimuli like interferon-γ (IFN-γ), tumor-necrosis
factor (TNF), and lipopolysaccharide (LPS). M1 macrophages secret pro-inflammatory cytokines
and oxygen and nitrogen radicals to help destroy foreign organisms and tumor cells [1, 8]. On the
other hand, polarization into the M2 phenotype involves interleukin-4 (IL-4), IL-13, and
transforming growth factor β (TGF-β), leading to the production of immunosuppressive cytokine
IL-10 [9]. M2 macrophages are involved in the resolution of inflammatory responses, by playing
roles in debris scavenging, tissue remodeling, and angiogenesis [1, 8, 9].
Recently, tumor-associated macrophages (TAMs), macrophages localized in tumors or
tumor-enriched niche, have gained significant interest in the field of cancer therapy [10-12].
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TAMs are a prominent component of solid tumors, often comprising a major fraction of the cell
mass [10]. TAMs are derived from monocytes recruited by tumor cells via soluble mediators like
CCL2 (chemokine (C-C) ligand 2) [13]. In tumor microenvironment, monocytes are exposed to
anti-inflammatory molecules like IL-4, IL-10, TGF-β and prostaglandin E2 and polarized to M2like macrophages [10, 13]. These macrophages possess poor antigen presenting ability and
produce soluble factors to suppress the immune system against tumors [10]. For example, TAMs
suppress the production of IL-12, a cell-stimulating cytokine that promote anti-tumor activities
of natural killer cells, T helper 1 cells (Th 1), and CD4+ T cells [14]. In addition, TAMs produce
chemokine CCL22 to mediate trafficking of regulatory T cells (Treg) and suppress tumorspecific T cell immunity [15]. TAMs can also encourage tumor invasion via non-immune
processes, such as the production of a high concentration of vascular endothelial growth factor
(VEGF), which promotes vasculogenesis and angiogenesis [16].
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Figure 1. (a) Origin of tissue-resident macrophages: bone marrow-originated monocytes (most
well-known), fetal liver-derived monocytes, and yolk sac-derived macrophages [5]. (b) Linear
scale designating two activation states of macrophages, M1 and M2, and responsible stimuli.
Figures adapted from [1].
1.3

Macrophages in drug delivery

1.3.1 Macrophages as target for drug delivery
Macrophages have long been an important target for drug delivery. For example,
antibacterial agents are delivered to macrophages for the treatment of intracellular infections,
such as tuberculosis, salmonellosis, and brucellosis. These infections are caused by bacteria
residing in host cells, which allow them to replicate, survive, and cause damages to the host.
Macrophages provide an immune-privileged niche and act as reservoirs for these intracellular
pathogens [17, 18]. Leishmania donovani, a deadly intracellular protozoan, also inhabits and
proliferates in macrophages to cause visceral leishmaniosis [19-21]. Infections with these
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pathogens are currently managed by antibiotics, but the therapeutic outcomes are disappointing
due to the inefficient delivery of these drugs to the pathogens in the macrophages [22, 23]. Drug
delivery systems that can target macrophages are expected to enhance co-localization of
antibiotics and intracellular pathogens and, thus, improve the therapeutic effects.
Macrophages are also latent reservoirs for human immunodeficiency virus type-1 (HIV1) [24]. Macrophages allow the entry of the virus via CD4, which interact with the envelope
glycoprotein gp120 of HIV-1 [25]. Macrophages can resist the cytopathic effect of HIV-1 and
disseminate the virus throughout the body due to the mobility and prevalence, thus making an
important therapeutic target for the treatment of HIV-1 infection [25]. Macrophages have also
been pursued as a therapeutic target for the treatment of Gaucher disease, a genetic disorder
leading to deficiency of lysosomal enzyme activity [26]. Since this enzyme dysfunction mainly
occurs in macrophages, efforts have been made to deliver replacement enzymes or enzyme
activators specifically to macrophages [26-28]. In addition, macrophages play a critical role in
rheumatoid arthritis (RA), as their overpopulation in the inflamed synovial membranes leads to
acute and chronic damages to the joints [29]. Hence, drug delivery systems that can specifically
inactivate or deplete macrophages in the joints have been of interest in the field of RA therapy
[30-32].
In cancer therapy, macrophages have typically been considered an undesirable
mechanism for premature clearance of NPs and, thus, a subject to avoid during the circulation.
However, with the increasing awareness of the complex roles of TAMs in tumor progression,
macrophages are revisited as a potential target in cancer therapy [11, 13, 33]. TAMs have been
targeted in two ways in cancer therapy: One is to deplete TAMs and prevent its tumor-promoting
activities, and the other is to reprogram TAMs into more M1-like pro-inflammatory phenotypes
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and enhance their immunostimulatory properties. These approaches employ chemotherapeutic
agents like 5-fluorouracil, docetaxel and trabectedin [13, 34-36], bisphosphonates like
zoledronate and alendronate [37, 38], inhibitors of specific signaling pathways [39], or cytokines
[40]. Trabectedin is a new marine alkaloid with anticancer activities, recently approved for the
treatment of soft tissue sarcoma [35, 41]. Germano et al. reported that trabectedin caused
selective depletion of monocytes and macrophages in blood, spleens, and tumors and reduction
of angiogenesis, suggesting that TAM inhibition may be the main mechanism of its anticancer
activities [36]. Docetaxel, a taxane anti-mitotic agent, was suggested to play multiple roles in
modulation of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts: it promoted the
apoptosis of immunosuppressive MDSCs in 4T1-neu mammary tumor-bearing mice and also
induced polarization of MDSCs toward an M1-like phenotype [42]. Bisphosphonates are
generally prescribed for the treatment of cancer-induced bone diseases and known to have direct
anti-tumor effects [38]. In addition, bisphosphonates are readily taken up by macrophages to
induce their apoptosis and inhibit the production of pro-angiogenic matrix metallopeptidase 9
(MMP-9) [38]. It was also shown that zoledronate helped TAMs to restore M1 antitumoral
phenotype, extending the overall survival of tumor-bearing mice [43]. In recent studies,
inhibitors of colony-stimulating factor 1 receptor (CFS1R) blocked the CSF1/CSF1R signaling
pathway decreased the number of TAMs and also reprogrammed remaining TAMs to enhance
their immunostimulatory properties [39]. Similarly, local delivery of interleukin-21 (IL-21)
induced TAM polarization from M2 to M1 phenotype, invoking their antitumor potential [40].
1.3.2 Macrophages as drug carriers
Macrophages or monocytes have been explored as potential carriers of anticancer drugs
and imaging agents due to the tropism to hypoxia and the ability to migrate and infiltrate into
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tumors [44, 45]. Macrophages can also migrate across the blood brain barrier to reach inflamed
brain tissues encountered in Alzheimer’s and Parkinson’s diseases [46]. To minimize immediate
effects on macrophages, drugs are first loaded in nanoparticles that can attenuate their release,
then attached on macrophages via non-covalent adsorption, ligand-receptor interactions, or
covalent coupling, or internalized into the macrophages prior to administration [46-48].
Brynskikh et al. reported that antioxidant enzyme (catalase), encapsulated in polyion micelles
(nanozymes) then loaded in bone marrow macrophages (BMMs), were accumulated and retained
in the brain better than nanozymes alone in mice with neuroinflammation, leading to mild
increase in a neuroprotective effect [49]. Macrophages were also used as a carrier of gold-silica
nanoshells to help infiltrate gliomas in vitro [50] and in vivo [51] and facilitate photothermal
therapy. Similarly, liposomal doxorubicin was loaded in macrophages to improve drug
penetration and retention in tumors [52]. The intravenously injected macrophages containing
liposomal doxorubicin showed greater drug delivery to subcutaneous and metastatic xenografts
and tumor suppression than liposomal doxorubicin alone [52]. These examples show the
feasibility of macrophages as carriers of nanomedicines to the regions of body that are difficult
to reach otherwise. On the other hand, preservation of macrophage and drug activities remains a
challenge in this approach. In case of cancer therapy, one should also mind the possibility of the
infiltrating macrophages stimulating tumor growth [51].

1.4

Drug delivery systems for intracellular delivery to macrophages
Microparticles and NPs have gained significant interest as drug carriers for macrophage-

targeted therapy. Particulate drug delivery systems in macrophage-targeted drug delivery have
several advantages in delivering drugs to macrophages in the RES organs. Particles can protect
drugs from degradation during circulation, readily reach the RES organs, and enter macrophages
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by phagocytosis. This section discusses liposomes, polymeric particles, dendrimers, and
nanogels, specifically designed for macrophage-targeted drug delivery (Table 1).

Table 1. Drug carriers for macrophage-targeted intracellular drug delivery
Formulation

Encapsulated
drug

Functions

References

PLGA NPs

Gentamicin

Enhanced antibacterial effects against
Listeria monocytogenes in J774a.1
macrophages (in vitro) and Brucella
melitensis infection in mice (in vivo)

[53, 54]

PLGA NPs

Isoniazid
analogue

Enhanced intracellular antibacterial
effect against intracellular
Mycobacterium tuberculosis in BMMs
(in vitro)

[55]

Mannosylated
PLGA NPs

Amphotericin B

Enhanced cellular uptake of
amphotericin B-loaded PLGA NPs in
J774a.1 macrophages (in vitro) and
biodistribution in macrophage-rich
organs in mice (in vivo); enhanced
antileishmanial activity against
promastigotes in J774a.1 macrophages
(in vitro).

[56]

Chitosan NPs

Ceftriaxone

Killed intracellular Salmonella
typhimurium in J774.2 macrophages
(in vitro)

[57]

Chitosan NPs

Ciprofloxacin

Equivalent to free ciprofloxacin in
killing Salmonella in Raw 264.7 and
Intestine 407 cells despite attenuated
drug release (in vitro); Reduced
dosage and frequency for effective
killing of Salmonella in diseased mice
(in vivo)

[58]

Core-shell NPs
from block
copolymers

Gentamicin

Enhanced antibacterial effects against
Salmonella in J774.1 cells (in vitro)
and in AJ646 mice (in vivo)

[59]
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Table 1. Continued
PAMAMerythromycin
dendrimeric NPs

A prodrug of
erythromycin

Suppressed the nitrile oxide level in
LPS activated RAW 264.7
macrophages (in vitro)

[60]

Mannose-PPI
dendrimeric NPs

Amphotericin B

Enhanced cellular uptake of mannosePPI dendrimeric NPs in J774a.1
macrophages (in vitro); Improved
parasite killing in mice infected with
Leishmania donovani amastigotes (in
vivo)

[61]

Liposomes

Gentamicin

Lowered morbidity in mice with
Salmonella dublin infection (in vivo)

[62]

MBSA or O-SAP
coated liposomes

Rifampicin

Enhanced rifampicin lung retention in
rats (in vivo); Enhanced intracellular
antimicrobial activity in alveolar
macrophages isolated from rats pretreated with liposome aerosols (in
vitro/in vivo)

[63]

Liposomes
Ciprofloxacin
prepared from
HSPC/DOPC/DCP

Increased drug retention in the
alveolar macrophages of rats infected
with pneumonia (in vivo)

[64, 65]

Liposomes
prepared from
DSPC/Chol

Vancomycin

Effective against MRSA in THP-1
macrophages (in vitro)

[66]

HA decorated
chitosan nanogels

Chlorin e6

Selectively taken up by RAW 264.7
macrophages as compared with L929
or NIH-3T3 fibroblasts (in vitro);
Prolonged retention of Chlorin e6 in
arthritic knees of mice (in vivo)

[67]

O-carboxymethyl
chitosan nanogels

Tetracyclin

Improved intracellular antimicrobial
efficacy (in vitro)

[68]

Thermoresponsive
HA nanogels

Distrylbenzene
derivative

Enhanced cellular uptake of
distyrylbenzene in RAW 264.7 cells
(in vitro)

[69]

Cholesteryl
pullulan nanogels

Antitumor
vaccine

Preferentially engulfed by medullary
[70]
macrophages (in vitro) and inhibited in
vivo tumor growth in mice
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Table 1. Continued
Dextran sulfate
nanogels

Chloramphenicol Enhanced intracellular killing of
Salmonella paratyphi in RAW 264.7
macrophages (in vitro)

[71]

* NP, nanoparticles; PAMAM, polyamidoamine; PPI, poly(propylene imine); MBSA,
maleylated bovine serum albumin; O-SAP, O-stearoyl amylopectin; HSPC, hydrogenated soy
phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DCP, dicetylphosphate;
DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; Chol, cholesterol; MRSA, methicillinresistant Staphylococcus aureus; HA, hyaluronic acid.
1.4.1 Liposomes
Liposomes are spherical vesicles composed of phospholipid bilayer surrounding an
aqueous space and have widely been used in cosmetic and pharmaceutical industries [72].
Liposomes are well suited for the macrophage-targeted therapy, due to the low toxicity,
flexibility in surface modification, and preferential uptake by the RES organs [73].
Gentamicin-loaded liposomes composed of phosphatidylcholine (PC),
phosphatidylglycerol (PG), cholesterol (Chol) and α-tocopherol were tested in a murine model of
fatal Salmonella dublin infection [62]. The gentamicin liposomes reduced the mortality
substantially, whereas free gentamicin was completely ineffective at the same dose [62]. Vyas et
al. produced rifampicin-encapsulated liposome aerosol for targeted delivery to alveolar
macrophages [63]. The liposomes were made of PC, Chol, and phospholipids with maleylated
bovine serum albumin (MBSA) or O-stearoyl amylopectin (O-SAP) as alveolar macrophage
specific ligands [63]. These liposomal formulations exhibited greater lung distribution of
rifampicin in rats, as compared to free drug or liposomes with no ligands, due to the preferential
uptake by the lung macrophages [63]. Consequently, lung macrophages isolated from the
animals pre-administered with targeted liposome aerosols resisted intracellular infection better
than those treated with drug solution or non-targeted liposomes [63]. Similarly, Chono et al. used
ciprofloxacin-loaded liposomes for treatment of respiratory intracellular bacterial infection and
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found superior delivery to alveolar macrophages and antibacterial effects to those of free
ciprofloxacin [64, 65]. An optional surface modification with mannose further potentiated the
antibacterial effects of the liposomes due to the increased liposome uptake via receptor-mediated
endocytosis [64]. Pumerantz et al. incorporated vancomycin, a glycopeptide antibiotic used for
the treatment of meticillin-resistant Staphylococcus aureus (MRSA), in liposomes made of
DSPC and Chol for the treatment of intracellular MRSA infection [66]. In contrast to the MRSAcontaining THP-1 macrophages incubated with free vancomycin, those treated with liposomal
formulation exhibited effective drug concentration in the macrophages after 24 h, resulting in
significant reduction of MRSA counts [66]. In addition to the above examples, other strategies
can be incorporated to maximize the targeted delivery to the macrophages, which will be
discussed in section 1.5.2.4 in detail.
1.4.2 Polymeric nanoparticles
Polymeric nanoparticles (NPs) are colloid systems prepared from the natural or synthetic
polymers, with an average diameter in the range of 10-1000 nm [74]. They may be nanospheres
made of solid matrix in which a drug is homogeneously distributed, or nanocapsules where drug
is encapsulated in a core surrounded by a polymeric shell [74]. Poly(lactic-co-glycolic acid)
(PLGA) is one of the most widely used synthetic polymers due to its biodegradability and
biocompatibility [75]. PLGA has been frequently used for targeted delivery of antibiotics to
macrophages for the therapy of intracellular infection.
Imbuluzqueta et al. used PLGA NPs as a carrier of a gentamicin derivative and observed
improved efficacy against intracellular pathogens, such as Listeria monocytogenes [53].
Gentamicin was modified to gentamicin-bis(2-ethylhexyl) sulfosuccinate (GEN-AOT) to
improve stability and drug loading in a carrier. GEN-AOT encapsulated in PLGA NPs
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outperformed free gentamicin or a micronized precipitate form of GEN-AOT in vitro, due to the
increased intracellular accumulation [53]. They later confirmed that gentamicin-AOT PLGA NPs
were effectively delivered to the liver and the spleen of a mouse, maintained the drug
concentration above the minimum inhibitory concentration (MIC) in both organs up to four days
and thus augmented the therapeutic activity against brucellosis [54]. PLGA NPs were also used
for intracellular delivery of isoniazid to murine bone marrow-derived macrophages (BMMs)
infected with Mycobacterium tuberculosis [55]. Similar to the previous approach, isoniazid was
hydrophobically modified for efficient encapsulation in PLGA NPs. The NPs helped the drug
enter macrophages and kill the mycobacteria resident in the intracellular granuloma [55].
Chitosan is a natural polysaccharide derived from the exoskeleton of crustaceans and has
been extensively used for mucoadhesive drug delivery and gene transfection [76]. Zaki and
colleges loaded ceftriaxone sodium, a third-generation cephalosporin, in the chitosantripolyphosphate NPs and demonstrated efficient killing of intracellular Salmonella typhimurium
in J774.2 macrophages, which free drug could not kill [57]. The authors attribute the
antibacterial activity to the enhanced cellular uptake as well as the antimicrobial activity of
chitosan itself [57]. Gnanadhas et al. developed hollow nanocapsules based on layer-by-layer
complexation of oppositely charged polyions chitosan and dextran sulphate, in which
ciprofloxacin was loaded post hoc via pH manipulation [58]. Encapsulation in these
nanocapsules improved the potency of the drug against intracellular salmonella infection and
reduced the dosing frequency due to the prolonged drug retention in the blood and the organs
[58]. Ranjan et al. made a gentamicin NPs by forming electrostatic complexes with polycationic
gentamicin and anionic polymers (block copolymers of poly(ethylene oxide-b-acrylate) (PEO-bPAA-) or poly(ethylene oxide-b-methacrylate) (PEO-b-PMA-), blended with PAA-), which
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provided sustained release of gentamicin [59]. This formulation reduced the numbers of viable
bacteria in the liver and the spleen to a greater extent than free gentamicin in AJ 646 mice
infected with salmonella [59].
1.4.3 Dendrimers
Dendrimers have gained interest as a carrier of drugs, genes, and imaging agents due to
their unique properties such as the uniform size, high control over molecular structure, versatile
surface functionality and internal cavities available for encapsulation of these agents [77].
Erythomycin-2’-glutarate, a prodrug of erythromycin, was conjugated to the poly(amidoamine)
(PAMAM) dendrimer derivatives via an ester bond to form NPs with an average size of 5 nm
[60]. The NPs maintained anti-bacterial activity of erythromycin and showed a greater antiinflammatory effect (suppression of nitrile oxide production) on lipopolysaccharide-activated
RAW 264.7 macrophages than free drug or the carrier, demonstrating their therapeutic potential
in the local treatment of periprosthetic inflammation [60]. Recently, surface-engineered
dendrimeric nanoconjugates were tested as a carrier of amphotericin B (AmB), targeted to
intracellular Leishmania donovani in macrophages [61]. AmB was physically loaded in the fifthgeneration poly(propyleneimine) (PPI) dendrimers conjugated with mannose, a targeting ligand
for mannose receptors of macrophages [61]. AmB loaded in mannose-conjugated dendrimers
showed a 50% inhibitory concentration (IC50) of 0.0385 µM against intracellular L. donovani in
the J774.1 macrophages, substantially lower than those of free AmB or liposomal AmB,
indicating improved intracellular parasite killing activity [61]. Moreover, the dendrimeric
formulation showed improved pharmacokinetics and biodistribution with more favorable toxicity
profiles [61].
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1.4.4 Nanogels
Nanogels are nanoscale-hydrogels composed of cross-linked polymer networks. Its
popularity as drug carrier stems from the stimuli-responsiveness, the potential for controlled drug
release, design flexibility, and good biocompatibility [78]. Several natural polysaccharides, such
as hyaluronic acid (HA), chitosan, pullulan or their combinations, have been used as a platform
of nanogels. Drugs are typically loaded via electrostatic interactions with polysaccharides or
hydrophobic interactions with hydrophobic moieties introduced to the polysaccharides.
Schmitt et al. developed HA-decorated chitosan nanogels for local delivery of
photosensitizers to macrophages in the inflamed articular joints [67]. The nanogels were
prepared by ionic gelation of chitosan in pentasodium triphosphate, in which anionic
photosensitizers were encapsulated by simple incubation [67]. HA was introduced as a ligand
targeting CD44 on the macrophages as well as a biocompatible surface modifier.
Photosensitizers encapsulated in the nanogels were superior to free agents in phototoxicity on
RAW 264.7 murine and THP-1 human macrophages and retention in the joints in a murine
model of antigen-induced arthritis [67]. Intraarticular injection of the nanogels combined with
25 J/cm2 light irradiation resulted in a similar level of serum amyloid A, an indicative of acute
inflammation, as the prednisolone treatment, a corticoid used in clinic for rheumatoid treatment
[67]. Similarly, chitosan nanogels were used as a carrier of tetracycline to address intracellular S.
aureus infection [68]. Tetracycline was incorporated in calcium-crosslinked O-carboxymethyl
chitosan nanogels. S. aureus counts inside the THP-1 macrophages were reduced to 2.5% when
treated with the nanogels, much lower than 15% by free tetracycline treatment, indicating
increased intracellular antimicrobial efficacy [68]. A recent study showed that chloramphenicol
encapsulated nanogels made of dextran sulfate and a chitosan crosslinker reduced the counts of
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Salmonella paratyphi in RAW 264.7 macrophages to a greater extent than the free drug
treatment [71].
Fernandes et al. developed thermoresponsive nanogels based on HA, which had a size in
the range of 150-200 nm at body temperature [69]. HA was grafted with copolymers of
oligo(ethylene glycol) methacrylates, which self-associated into hydrophobic microdomains at
an elevated temperature to incorporate hydrophobic drugs [69]. The HA-based nanogels loaded
with a distrylbenzene derivative (DSB), a hydrophobic two-photon fluorescence dye, were taken
up by RAW 264.7 cells in a dose-dependent manner, while the cells treated with a simple
mixture of DSB and plain HA did not show any fluorescence, demonstrating the potential of the
nanogels as carriers of hydrophobic drugs to phagocytic cells [69]. Muraoka et al. developed a
medullary macrophage-targeted vaccine delivery system based on pullulan nanogels to enhance
antitumor immunity [70]. Pullulan was first modified with cholesteryl groups to form selfassemblies and loaded with polypeptides as a tumor antigen [70]. Upon subcutaneous injection to
mice, these nanogels travelled to the draining lymph nodes and were selectively and efficiently
engulfed by medullary macrophages, which provided effective cross-presentation to vaccinespecific CD8+ T cells, effectively suppressing tumor growth [70].
1.4.5 Others
Other systems include NPs based on drug-carrier conjugates and hybrids of two material
systems. Semiramoth et al. developed self-assembled NPs with a conjugate of penicillin G
(PNG) and squalene to address intracellular bacterial infection. The NPs were taken up by
macrophages via endocytosis and released PNG in the acidic lysosomal pH, effectively killing
intracellular S. aureus in J774a.1 macrophages, unlike free PNG [79]. Gupta and colleagues
developed liposome-like NP assemblies (“lipo-polymerosome”) consisting of glycol chitosan
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stearic acid copolymer and lipids, in which AmB was intercalated [80]. The AmB-loaded lipopolymerosomes showed greater serum stability, safety profiles, and antileishmanial efficacy than
traditional liposomal formulations [80]. The lipo-polymerosomes were further modified with
lectin to achieve specific uptake by infected macrophages [81]. The lectin-modification also
increased the accumulation of the lipo-polymerosomes in the liver, spleen, and lung, the main
target organs in leishmania-infected subjects [81]. Maretti et al. have developed solid lipid
microparticles (SLM) composed of sodium taurocholate and stearic acid for inhaled antibiotic
therapy of tuberculosis [82]. The SLM had a desirable aerodynamic diameter (1.15 µm) for
transport to the alveolar epithelium, negative surface charges for preferential phagocytosis by the
resident macrophages, and hydrophobicity for encapsulation and retention of rifampicin [82].

1.5

Challenges in drug delivery to macrophages
The previous section shows several examples of drug delivery systems with promising

results in the treatment of intracellular bacterial infection of macrophages. To translate this
promise to broader applications, a number of challenges remain to be overcome, such as nonspecific biodistribution, inefficient cellular uptake, poor intracellular trafficking, insufficient
drug release, and development of drug resistance. From a holistic standpoint, these challenges
are often “synergistic”, because solutions to these challenges may conflict with each other. For
example, successful control of biodistribution of a drug is predicated on the stability of drug
carriers in the physiological environment, but the stability can in turn compromise the drug
activity at target organelles. A stimuli-sensitive carrier is introduced to facilitate intracellular
drug release, however, often at the cost of extracellular stability. An ideal drug carrier requires a
fine balance between such conflicting requirements. Therefore, systematic understanding of the
existing challenges and potential solutions is critical to the design of efficient drug carriers.

17
1.5.1 Pharmacokinetics and biodistribution
Circulating NPs are mostly cleared up by the mononuclear phagocytes in the liver and
spleen (RES). This is a significant problem if the RES is not an intended target, therefore, NPs
targeting other organs and tissues (such as tumors) are typically coated with ‘stealth’ polymers
on the surface to avoid phagocyte recognition during circulation. However, in applications
targeting macrophages in the liver or spleen (e.g., intracellular infections), NP uptake by the RES
is considered advantageous and actively exploited. Imbuluzqueta et al. reported that
intraperitoneally administered free gentamicin mainly accumulated in the kidneys and showed
signs of nephrotoxicity in mice, whereas a gentamicin derivative encapsulated in the PLGA NPs
showed increased accumulation in the liver and spleen with no apparent toxicity in the kidneys
[54]. Similarly, AmB delivered with dendrimeric nanoconjugates showed an increased plasma
AUC and circulation half-life as well as greater biodistribution in the liver and spleen and
reduced kidney level as compared to free drug [61]. Liposomal ciprofloxacin also showed 12.6
fold higher AUC and 8.8 fold higher Cmax in alveolar macrophages than free ciprofloxacin after
pulmonary administration to rats with pneumonia infection [65].
On the other hand, in targeting macrophages in tissues other than the RES – such as
TAMs, it is important to concentrate NPs in tumors and have them to be specifically taken up by
the TAMs in tumors. To achieve this, Niu et al. modified the surface of doxorubicinencapsulated PLGA NPs with mannose and sheddable PEG (DOX-AS-M-NPs) [83]. Here, the
NP surface was decorated with PEG via acid-labile hydrazone bond, which could be hydrolyzed
in the acidity of microenvironment. The purpose was to reduce the RES uptake of the NPs during
circulation via PEG but allow the NPs to interact with TAMs via the exposed mannose ligands
after the NPs are extravasated to enter tumors [83]. The presence of sheddable PEG layer helped
reduce the liver accumulation and increase the tumor accumulation of doxorubicin (Fig. 2) [83].
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Consistently, DOX-AS-M-NPs were more effective in controlling tumor growth than free
doxorubicin [83]. Depletion of TAMs by zoledronic acid treatment decreased doxorubicin
accumulation in tumor, confirming TAMs as the therapeutic target of DOX-AS-M-NPs [83].

Figure 2. Biodistribution of DOX in B16-F10 tumor-bearing mice. Representative ex vivo
fluorescence images of tumors and major organs 6 h after intravenous injection with PBS, DOX,
DOX-NPs (DOX-incorporated PLGA NPs), DOX-M-NPs (DOX-NPs surface-modified with
mannose but not PEGylated), DOX-AI-M-NPs (DOX-NPs surface modified with mannose and
PEGylated with an acid-insensitive linker), or DOX-AS-M-NPs (DOX-NPs surface modified
with mannose and PEGylated with acid-sensitive linker). T, tumor; K, kidney; H, heart; Lr, liver;
S, spleen; Ln, lung. Reprinted with permission from reference [83]. Copyright (2014) American
Chemical Society.
While the majority of current approaches aim to deliver NPs to macrophages that are
already present in target tissues, NPs may first target blood-borne macrophages or their
precursors to take advantage of their motility and tumor-tropism. Smith et al. demonstrated that
single-walled carbon nanotubes (SWNTs) were taken up by a subset of circulating monocytes
and delivered to the tumor interstitium via the monocytes [84]. RGD peptide conjugated to
SWNTs further increased the monocyte-mediated delivery into tumors, likely due to the
interaction between RGD presented on the cell surface and the integrin cognate in tumor
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intersititium [84]. This study demonstrates that circulating monocyte/macrophages may offer
additional means to deliver NPs and leverage passive extravasation into target tissues.
1.5.2 Cellular uptake by macrophages
Once a drug carrier arrives at target tissues, the next critical step is to transport the drug
from the outside of target cells to the interior. The carrier’s role is critical in this step if the drug
itself is unable to cross the cell membrane due to the polarity (e.g., gentamicin [85]) or the size
(e.g., proteins or peptides). The popularity of NPs or microparticles in macrophage-targeted drug
delivery stems in large part from the fact that they can enter macrophages via specialized
endocytosis mechanisms such as phagocytosis, micropinocytosis, clathrin-mediated endocytosis,
or caveolae-mediated endocytosis. Various physicochemical properties determine the efficiency
of macrophage uptake of the particles. This section discusses size, shape, surface charge and
surface ligands as the main contributors.
1.5.2.1 Particle size
The particle size ranges preferable for macrophage uptake vary with the type of particles
and tested cell lines [86-88]. Epstein-Barash et al. compared liposomes of different sizes (80-650
nm) with similar surface charges and observed more efficient uptake of larger liposomes (650
nm) by human monocytes (Fig. 3a) [87]. On the other hand, when murine J774a.1 macrophage
cell line was incubated with fluorescent chitosan particles of different sizes (430 nm, 1.9 µm and
4.8 µm), the extent of cellular uptake was in the order of 1.9 µm > 430 nm > 4.8 µm (Fig. 3b)
[89].
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Figure 3. (a) Liposome uptake by human monocytes. (b-e) Internalization profiles of J774A.1
cells after 24 h incubation with chitosan particles of different sizes. (b) The confocal microscope
images of J774A.1 cells incubated with 430 nm chitosan particles, (c) 1.9 µm particles, and (d)
4.8 µm particles. (e) Cellular uptake measured by flow cytometry. Reprinted with permissions
from reference [87, 89]. Copyright (2010) Elsevier.

It is worth noting that the in vitro cellular uptake does not necessarily translate to in vivo
due to other physiological factors contributing to the distribution of particles. When liposomes of
100-2000 nm were incubated with alveolar macrophages in vitro, cellular uptake increased with
the increase of the size until 1000 nm and reached a plateau [90]. On the other hand, in vivo
macrophage uptake continued to increase with the particle size over the whole range, due to the
increasing extent of opsonization by lung surfactant proteins [90]. Ohashi et al. reported the
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opposite case [91]. They produced inhalable mannose microparticles containing PLGA NPs
(200-400 nm) (PLGA NP/Man MP), which rapidly dissolved to release PLGA NPs in aqueous
media (cell culture medium or lung fluid). Alveolar macrophage uptake of PLGA NP/Man MP
and PLGA microparticles of a comparable size (2 µm) was compared in vitro and in vivo.
Consistent with other studies, PLGA microparticles were better taken up by macrophages than
PLGA NP/Man MP (= PLGA NPs in cell culture medium) in vitro. In vivo macrophage uptake
showed the opposite trend, due to the greater mucociliary clearance of PLGA microparticles
[91].
1.5.2.2 Surface charge
Charged particles are more likely to be taken up by macrophages than neutral particles.
Cellular uptake was enhanced with the increase of the net charge, but no significant difference
was observed between cationic and anionic particles with the same net charges [87, 92, 93]. This
trend is different from the cases of non-phagocytic cells, where more positively charged particles
are favored for cellular uptake due to the electrostatic interactions [93].
1.5.2.3 Particle shape
Particle shape has significant impact on macrophage cellular uptake and may be exploited
for controlling the extent of drug delivery to macrophages. Champion et al. fabricated
polystyrene microparticles with different shapes such as spheres, rods and disks and evaluated
their alveolar macrophages uptake [94]. They observed that the local shape at the point of initial
contact with macrophages dictated whether the cells would spread on the particle surface or
phagocytose the particles [94]. Sharma and Smith later confirmed the dependence of
phagocytosis on the particle shape and refined the shape effect [95]. They reported that particle
shape influenced the attachment and internalization independently: the attachment of particles to
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macrophages was ranked in the order of prolate ellipsoids, oblate ellipsoids, and spheres, but in
case of internalization oblate ellipsoids were much more favored than spheres or prolate
ellipsoids [95]. The role of particle shape is explained by its effect on the actin-remodeling
process during phagocytosis: Macrophages binding to particles with a larger aspect ratio require
higher energy to perform actin remodeling, a process required for particle internalization, and
have greater difficulty in completing the process [94, 95].
1.5.2.4 Cell-interaction ligands
Macrophages display a variety of receptors such as mannose receptor, folic acid
receptors, Fc-receptors and fibronectin lipoproteins [96-99]. Particle surfaces are decorated with
ligands for these receptors to improve delivery efficiency to macrophages. In particular, mannose
is frequently used as a ligand for macrophage targeting due to the prevalence of the receptors
(CD206) [73, 96]. Several examples demonstrate the effectiveness of mannose ligands in
macrophage-targeted delivery. Attachment of mannose to PLGA or gelatin NPs increased their
cellular uptake by J774a.1 macrophages and biodistribution in the RES organs compared with
plain NPs [56, 100, 101]. Similarly, mannose decoration increased the macrophage uptake of
solid lipid NPs encapsulating rifabutin by six times and enhanced the drug concentration in the
lungs by 1.5 times upon intravenous injection [102]. Mannosylated liposomes also showed
superior cellular uptake by macrophages than plain liposomes in vitro and in vivo [64, 103, 104].
Macrophage uptake of mannosylated liposomes increased with the surface density of mannose
and was inhibited in the presence of excess mannan, a competitive ligand for mannose receptors,
confirming the receptor-mediated endocytosis of liposomes [105].
Folate receptors are expressed on the surface of activated macrophages, shown to be
upregulated in the macrophages in rheumatoid arthritis and pulmonary fibrosis [106-108].
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Folate-conjugated particles, such as liposomes, human serum albumin NPs and polymeric
nanosuspentions, exhibited enhanced macrophage uptake when compared with non-folated
particles [109-111]. Puig-Kroger et al. reported that folate receptor β (FRβ) was expressed on
M2-like macrophages stimulated by macrophage colony-stimulating factor (M-CSF) but not on
M1-like macrophages induced by granulocyte macrophage colony-stimulating factor (GM-CSF)
[111]. Consistently, the expression of FRβ was detected in M2-skewed (CD163+) primary and
metastatic TAMs [111]. The TAMs were able to internalize FITC-folates, indicating the potential
of FRβ as a marker for M2-like macrophage targeting [111]. This observation is consistent with
the report of Turk et al, which described preferential uptake of folate-conjugated liposomes by
TAMs in a murine model of ovarian cancer [112].
Peptides are also investigated as a macrophage-targeting ligand. Tufsin is a tetrapeptide
(TKPR) derived from the Fc portion of immunoglobulin G and can bind to macrophages and
enhance their phagocytosis, migration, anti-bacteria and anti-tumor activities [113-115]. Jain and
colleagues developed tuftsin-modified alginate NPs and observed higher cellular uptake by
J774a.1 macrophages than non-modified or scrambled peptide-modified alginate NPs [114].
Accordingly, the tuftsin-modified NPs served as an efficient gene carrier to macrophages [114].
Recently, Cieslewicz et al. discovered a unique peptide sequence, called M2pep
(YEQDPWGVKWWY) by phage display technique, which can specifically target M2
macrophages [116]. The M2pep was fused with a proapoptotic KLA peptide
(KLAKLAKKLAKLAK) and administered to tumor-bearing mice for selective reduction of
TAM populations [116]. The M2pepKLA fusion peptide extended the survival of tumor-bearing
animals as compared to those treated with M2pep or KLA peptide fused with scrambled M2pep,
validating M2pep as the targeting ligand to TAMs [116].
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1.5.3 Intracellular trafficking and drug release
For internalized drug carriers to provide a therapeutic effect, they need to be transported
to the target organelles and release the drug timely. In intracellular infections, the target
organelle is the location of bacterial residence: cytosol for Listeria [117], vacuoles for
Salmonella [118], and endoplasmic reticulum and phagosomes for Brucella [119]. When a
foreign substance is introduced into the cells, the endocytic vesicles are rapidly transported to
early endosome/phagosomes and subsequently fused with sorting endosomes, where the fate of
the internalized material is determined [120]. Particles are typically trafficked to late endosomes
with pH 5-6 and later relocated to lysosomes with even lower pH (around 4-5) and numerous
degradative enzymes such as glucosidases, hexosaminidases, DNase and cathepsins [121, 122].
For drugs unstable in acidic pH and/or sensitive to lysosomal enzymes (e.g., nucleotides or
proteins/peptides), it is critical to design a delivery system that escapes the endo/lysosomes
before drug destruction takes place. Equally importantly, the drug needs to be released in a
timely manner at the target organelles to exert an action.
Three unique features of intracellular environment are typically exploited for controlling
intracellular behaviors of drug carriers: acidic pH of intracellular organelles, lysosomal enzymes,
and relatively high reductive potential [123]. Some of these approaches are applicable to
macrophage-targeted intracellular drug delivery, since macrophages display acidic phagosomal
pH [124, 125] and contain abundant digestive enzymes including lysozyme [126]. Common
strategies to achieve endosomal escape include the use of cationic polymers, pH-sensitive
polymers and cell-penetrating peptides [120, 127, 128]. Lutwyche et al. encapsulated gentamicin
in liposomes that could fuse with endosomal membranes in a pH-sensitive manner [129]. The
fusogenicity came from dioleoylphosphatidylethanolamine (DOPE), and pH-sensitivity from the
inclusion of N-succinyl group to DOPE [129]. The intracellular anti-bacterial effect against
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salmonella and listeria in J774.1 macrophages was greater with liposomes containing N-succinyl
DOPE than those with non-fusogenic DOPC [129]. The enhanced anti-bacterial activities were
explained by the efficient destabilization of liposomes (i.e., drug release out of liposomes) at
endosomal pH and the fusogenic activity of lipids leading to endosomal escape (i.e., drug release
out of endosomes) [129]. Recently, Ortega et al. reported mannosylated NPs with a block
polymer of 2-(dimethylamino) ethyl methacrylate (DMAEMA), butyl methacrylate (BMA) and
2-propylacrylic acid (PAA) for the delivery of siRNA to TAMs [130]. Here, the combination of
DMAEMA and PAA served as a pH-sensitive portion of the polymer to facilitate the endosomal
escape and cytoplasmic delivery of siRNA [130]. Another pH-responsive approach employs an
acid-labile linker between a drug and a carrier, which allows drug release in acidic organelles.
For example, the self-assembled PNG-squalene conjugate showed pH-sensitive drug release of
PNG in lysosomes [79]. In this case, the carrier did not contain a distinct mechanism for
endosomal escape; thus, the NPs did not effectively co-localize with the bacteria-containing
organelles. Nevertheless, PNG released in the acidic organelles showed anti-bacterial activity
against intracellular S. aureus, presumably due to the protonation of the released PNG which
enabled its diffusion across the intracellular membrane [79]. The microenvironment created by
intracellular bacterial infection was used as a stimulus to induce drug release: Xiong et al.
developed vancomycin-encapsulated polymeric nanogels, composed of polyphosphoester core
and PEG shell intercalated by lipase-sensitive poly (ε-caprolactone) (PCL) layer [131]. Upon
exposure to bacterial lipases in the cells, the nanogel released vancomycin with the degradation
of PCL layer, killing intracellular S. aureus more effectively than free vancomycin [131].
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1.6

Summary
Nano- and microparticulate drug carriers have proven useful for intracellular delivery of

antibiotics to macrophages. Particulate carriers with optimal physicochemical properties are
readily collected in the RES, thus minimizing systemic toxicities, and facilitate cellular uptake of
hydrophilic antibiotics, which would otherwise not be able to cross the cell membrane and access
intracellular pathogens. Lessons learned from the success of intracellular antibiotics delivery
may be extended to broader applications involving organs other than the RES, such as tumors,
where macrophages acquire pathological roles and help aggravate the disease progression.
However, one should avoid reductionist approaches in designing macrophage-targeted drug
delivery systems, because the plasticity and heterogeneity of macrophages are controlled by
intricate interplay of their environment and the breach of this balance may lead to unexpected
consequences. Moreover, one should not ignore potential immunomodulatory effects of drug
carriers, given the native role of macrophages as the primary defender against exogenous
materials. With these cautions in place, rationally designed drug carriers can make a significant
contribution to macrophage-targeted drug delivery. After all, macrophages are easier to interact
than to avoid, more accessible and prevalent than other tissues. As the old saying goes “if you
can’t beat them, join them”.

1.7

Research Objective and Introduction to Chapters
Intracellular infection is a significant medical problem caused by intracellular bacteria,

such as Salmonella Typhimurium, Mycobacterium tuberculosis or Staphylococcus aureus. These
pathogens avoid immune defense mechanisms by hiding in host cells and propagate the
infection. In particular, macrophages are main hosts of intracellular pathogens in chronic
infectious diseases and, thus, pursued as a therapeutic target for intracellular delivery of
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antibiotics. However, hydrophilic antibiotics generally fail to accumulate efficiently into
macrophages due to highly hydrophilic nature. The poor intracellular bioavailability of
antibiotics reduces the efficacy of the treatment and requires repeated dosing regimen,
potentially promote resistance development.
Nanoparticulate (NP) delivery system is considered appealing for drug delivery to
macrophages, since macrophages are uniquely suited to take up foreign particulates. As
discussed above, liposomal nanoparticles have been the most widely used for encapsulation of
antibiotics. However, they generally suffer from low drug loading (drug/NP) and encapsulation
efficiency (drug encapsulated/drug added) [132-140], which necessitates the administration of
high amounts of excipients to reach intracellular concentrations as well as increase
manufacturing cost. In addition, the encapsulated hydrophilic drug is slowly released from the
carrier since liposomes have low permeability to these hydrophilic drugs [141], minimizing the
effective drug concentration that reaches the intracellular target and thereby increasing the risk
for developing antibiotic resistance.
Given the limitations of existing NP systems for antibiotics delivery, we aim to develop
polymeric nanoparticulate delivery systems, which can efficiently encapsulate antibiotics and
release the cargo to the target site, intracellular bacteria in macrophages, promptly. In particular,
we are interested in delivering cationic antimicrobial peptides (CAMPs), a new class of
antibiotics. CAMPs are promising antimicrobial agents due to their high potency, broad activity
spectrum, and a relatively low potential for resistance development [142]. However, CAMPs
suffer from non-specific biodistribution and susceptibility to enzymatic degradation and, thus,
benefit greatly from a new carrier.
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The objective of my thesis project is to develop a nanoparticle system as a macrophagespecific carrier of antibiotics. To accomplish this objective, I pursued three specific aims: (i) To
engineer nanoparticles that can encapsulate hydrophilic drugs with high loading efficiency; (ii)
To control the particle size and drug release for preferential macrophage uptake and timely
exposure to intracellular pathogens; (iii) To evaluate the effectiveness of the nanoparticles in a
murine model of intracellular bacterial infections.
This thesis discusses three particle platforms designed for intracellular delivery of
antibiotics. In Chapter 2, we used zwitterionic chitosan (ZWC) as the carrier of two CAMPs,
WR12 and RRIKA. ZWC is a pH-sensitive material, which forms a complex with CAMPs at
physiological pH but release the cargo at lysosomal pH. Since this approach is solely dependent
on the electrostatic interaction, ZWC was partially crosslinked to enhance the stability. Chapter 3
focuses on vancomycin delivery to the intracellular MRSA infection. To overcome poor
intracellular delivery of vancomycin, we developed a particle formulation (PpZEV) based on a
blend of polymers with distinct functions: (i) PLGA (P) serving as the main delivery platform,
(ii) PEG-PLGA (p) to help maintain an appropriate level of polarity for timely release of
vancomycin, (iii) Eudragit E100 (E) to enhance vancomycin encapsulation, and (iv) ZWC (Z) to
trigger pH-sensitive drug release. The PpZEV NP was further optimized and tested in a mouse
model of intracellular infection and discussed in Chapter 4. We also developed a novel particle
engineering method based on polymerized tannic acid, which is simple, inexpensive and ecofriendly. Three hydrophilic antibiotics (RRIKA, vancomycin and polymyxin B) and one model
DNA are encapsulated in polymeric tannic acid nanocapsules. The result is summarized in
Chapter 5.
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ENCAPSULATION OF CATIONIC ANTIMICROBIAL
PEPTIDES IN POLYMERIC NANOPARTICLES FOR
INTRACELLULAR DELIVERY

2.1

Introduction
Intracellular bacterial pathogens are bacteria that can reside, survive and replicate in the

intracellular compartment of the host cells using the cells as a niche for avoiding immune
defense mechanisms [1]. These pathogens preferentially infect phagocytes, such as macrophages,
and spread via blood and lymphatic circulations, then infect organs like liver and spleen to cause
the damage to the host [2]. Classically, Listeria monocytogenes, Brucella abortus, Chlamydia
trachomatis, Mycobacterium tuberculosis and Salmonella enterica are considered intracellular
bacterial pathogens and cause infectious diseases like listeriosis, brucellosis, tuberculosis and
salmonellosis [3]. Macrophages are the first defender cells that are supposed to kill and digest
ingested bacterial pathogens by taking them into phagolysosomes. However, intracellular
bacterial pathogens developed a way to produce ‘silent’ infection site inside cells and escape
from the intracellular bactericidal effects [4, 5] via different survival mechanisms. For example,
Listeria and Shigella can survive inside phagocytic and non-phagocytic cells by escaping from
phagocytic vacuoles to the cytosol by pore-lysing substances, such as listeriolysin O in listeria,
which can disrupt the vacuole membrane [6], thereby avoiding the endolysosomal degradation.
Pathogens like Salmonella and Mycobacterium can arrest the maturation of phagosomes at
specific phages and prevent phagosome-lysosome fusion [7, 8]. They survive in the phagosomes
in a dormant state and build latent infection that can last for years. Brucella, Chlamydia, and
Legionella have a way to segregate from the endocytic pathway and create a stable niche inside
host cells for intracellular replication and thus avoid endolysosomal degradation. Staphylococcus
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aureus is traditionally considered extracellular bacteria, but due to its ability to infect
professional and non-professional phagocytes, it is also classified as intracellular bacteria. S.
aureus can replicate in the phagosome or the cytoplasm for several days [9, 10]. For effective
treatment of intracellular bacterial infection, infection with these pathogens are currently
managed by antibiotics, but the therapeutic outcome is disappointing because the delivery of
these drugs to the intracellular bacteria is inefficient and the resistance to the existing antibiotics
is also growing. Therefore, it is critical to develop a different type of antimicrobials that can
efficiently eradicate intracellular bacteria without facing bacterial resistance.
Cationic antimicrobial peptides (CAMPs) have gained increasing interest as a promising
new class antibiotic. CAMPs can treat multidrug-resistant bacteria due to their high potency,
broad spectrum and a relatively low potential for resistance development. They are produced by
living organisms as a non-specific innate immune response to pathogenic microorganisms like
bacteria, fungi, parasites, and some viruses. CAMPs are usually made up of 10 – 50 amino
acids. While they come with diverse sequences and structures, CAMPs do share common
features to function as potent antibiotics [11]. First, as the name indicates, CAMPs are cationic
peptides, containing positively charged amino acids like arginine and lysine. This feature allows
them to preferentially interact with bacteria cell membranes rather than eukaryotic membranes.
The differential sensitivity comes from the fact that prokaryotic cells have anionic lipids exposed
on the surface whereas eukaryotic cells contain anionic lipids in the monolayer facing the interior
of the cells [12]. Second, CAMPs are amphiphilic molecules with alternation of hydrophobic
amino acids and polar residues in the primary structure. The amphiphilic topology is critical to
this process, because hydrophobic domains establish direct interaction with the membrane lipid
and hydrophilic regions either interact with phospholipid head groups or face the lumen of the
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pores [13]. Although the exact killing mechanism of CAMPs is yet to be established, it is
generally accepted that the antimicrobial activity of CAMPs is achieved through physical
disruption of cytoplasmic membrane by forming transmembrane pores [13]. Since the target is
the cell membrane, bacteria are less likely to develop resistance to the CAMPs, unlike
conventional antibiotics which act on specific intracellular targets that can be readily mutated.
Despite the benefits of CAMPs as potential future antibiotics, several limitations hamper
their clinical development, such as host toxicity, susceptibility to enzymatic degradation and
non-specific biodistribution. In addition, due to the large size relative to the small molecule
antibiotics, CAMPs are not readily taken up by the host cells and reach the intracellular bacteria
resided inside macrophages. To take full advantages of CAMPs, it is necessary to develop an
appropriate delivery system which can protect CAMPs during circulation and bring them
specifically to the target cells and intracellular pathogens.
In this study, we aim to develop a polymeric nanoparticle formulation that can efficiently
encapsulate and deliver CAMPs to the intracellular bacteria resident in macrophages. WR12 and
RRIKA are selected as model antimicrobial peptides due to their high potency to the planktonic
bacteria and low toxicity to the host cells (Fig. 4). Zwitterionic chitosan (ZWC), a chitosan
derivative, was synthesized to complex with CAMPs. ZWC shows negative charges at relatively
high pH and positive charges at low pH. Due to this pH-sensitivity, it can form an electrostatic
complex with cationic antimicrobial peptides at physiological pH but dissociate from the carrier
at lysosomal pH. The particles size of the complex is controlled between 500-1000 nm to make it
compatible with intravenous injection (< 1 µm) [14] while satisfying the size range preferable for
macrophage uptake (500 nm - 3 µm) [15]. The underlying hypothesis of this approach is that the
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NP formulation can protect CAMPs in circulation, enter macrophages via phagocytosis, and kill
the intracellular pathogens by releasing CAMPs in a pH-sensitive manner.

Figure 4. Antimicrobial activity of two CAMPs (WR12 and RRIKA) against planktonic and
intracellular bacteria. (a) Minimal inhibitory concentration (MIC) of WR12 and RRIKA for
different bacterial strains. (b) Intracellular antimicrobial activity of WR12 and RRIKA against
Listeria and Salmonella. With the courtesy of Dr. Mohamed F. Mohamed (Seleem lab).
2.2

Materials and Methods

2.2.1 Materials
WR12 peptide (Sequence: RWWRWWRRWWRR) and RRIKA peptide (Sequence:
WLRRIKAWLRRIKA) were synthesized by Genscript Biotech (Piscataway, NJ). Succinic
anhydride, fetal bovine serum (FBS) and Mueller-Hinton broth (MHB) were purchased from
Sigma-Aldrich (St. Louis, MO). Chitosan (MW ~ 15,000) and polyvinyl alcohol (PVA,
MW~6000) weres obtained from Polyscience, Inc. (Warrington, PA). PLGA (50:50 LA: GA,
0.15-0.25 dL/g, acid-terminated) was purchased from LACTEL® (Denver, CO). Eudragit E100
was a gift from Evonik (Darmstadt, Germany), Dichloromethane (DCM) and acetonitrile (ACN)
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were purchased from Fisher Scientific (Hampton, NH). Dulbecco's Modified Eagle's medium
(DMEM) and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagent
were purchased from Life Technology (Carlsbad, CA). Trypticase soy broth (TSB) and
Trypticase soy agar (TSA) were purchased from Becton-Dickinson (Cockeysville, MD).
Deionized (DI) water was obtained from a Milli-Q ultrafiltration system (Millipore, Billerica,
MA).
2.2.2 Synthesis of zwitterionic chitosan
Zwitterionic chitosan (ZWC) was synthesized according to the previously reported
method with minor modification [16]. In short, chitosan was dissolved in 1% acetic solution and
centrifuged at 3,724 rcf for 10 min. The supernatant was collected and lyophilized, rendering an
acetate salt form of chitosan. Four hundred (ZWC0.7) or sixty milligrams (ZWC0.3) of chitosan
acetate was dissolved in 60 mL deionized (DI) water, and the pH was adjusted to pH 6.0 by 0.1N
NaHCO3, followed by the addition of 60 mg succinic anhydride at room temperature (RT) with
continuous stirring. The reaction was maintained at pH 6.0 – 6.5 for one hour and then adjusted
to pH 7.5 for overnight reaction using 0.1N NaHCO3. The product was purified using dialysis
membrane (MWCO: 3.5 kDa) against DI water and lyophilized. The synthesized ZWCs were
characterized by measuring the surface charge of ZWC at different pH by a Malvern Zetasizer
Nano ZS90 (Worcestershire, UK). ZWC was dissolved in 10 mM NaCl with a concentration of
0.3 mg/mL, and the solution pH was adjusted from high to low by 0.1N HCl solution. The
degree of succinylation ratio was evaluated by 1H NMR spectroscopy.
2.2.3 Synthesis of thiolated ZWC
Forty milligrams of ZWC0.7 was dissolved in 10 mM phosphate buffer as 3 mg/mL. A
hundred microliters of DMSO containing 17 mg of (N-Succinimidyl 3-(2-pyridyldithio)-
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propionate) (SPDP) were added dropwise to the ZWC solution and the mixture was allowed to
react overnight with vigorous stirring. The mixture was treated with 957 mg of 1,4-Dithiothreitol
(DTT) at pH 5 for 3 hours. The product was purified by centrifugal filtration tubes (MWCO: 3
kDa) and lyophilized. The degree of thiolation was detected by Ellman’s reagent (DTNB, 5,5'Dithiobis-(2-Nitrobenzoic Acid)), based on the calibration curve generated by known
concentrations of cysteine standards solubilized in 10 mM pH 7.4 phosphate buffer.
2.2.4 Preparation and characterization of ZWC/CAMPs complex
ZWC/CAMPs or ZWC-SH/CAMPs complex was prepared by mixing 25 μL 10 mg/mL
WR12 or RRIKA DMSO solution with 0.5 mL 1 mg/mL ZWC (0.7 or 0.3) dispersed in 10 mM
pH 7.4 phosphate buffer. The particle formation was indicated by the turbidity development,
monitored at 570 nm using UV-Vis SpectroMax (Molecular Devices, San Jose, CA). To induce
crosslinking of thiols, the pH of the ZWC-SH/CAMP complex was increased to pH 8 and
incubated at room temperature for 1 h and returned to neutral pH by 0.1H HCl. The
hydrodynamic diameter and zeta potential of the complex was measured by dynamic light
scattering (DLS) using a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). The
stability of the complex was tested in the presence of PBS and/or 50 mg/mL human serum
albumin aqueous solution.
2.2.5 NP preparation using PLGA as the matrix
PLGA/WR12 (PW) NP. WR12 was encapsulated in the PLGA NPs by the oil-in-water
(O/W) single emulsion solvent evaporation method. Two milligrams of WR12 dissolved in 400
µL DMSO was added to 2 mL DCM containing 20 mg PLGA. The organic phase was emulsified
in 20 mL of 1% PVA solution with a Silverson® homogenizer (East Longmeadow, MA) at
5,000 rpm for 3 min. The resultant was dispersed to 40 mL DI water and stirred for 1 hour at
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room temperature. The DCM remnant was completely removed by rotary evaporator under
vacuum for 1 h. NPs were collected by centrifugation at 8,891 rcf for 15 min, washed twice with
DI water and lyophilized.
PLGA/ZWC/WR12 (PZW) NP. PZW NPs were prepared by the W1/O/W2 double
emulsion solvent evaporation method with a weight ratio of 20: 4: 2. Briefly, 4 mg of ZWC
solubilized in 0.4 mL DI water was emulsified into 2.4 mL organic phase (containing 20 mg
PLGA and 2 mg WR12, DCM: DMSO 83: 17, v/v) with a SONICS® Vibra-Cell ultrasonic
liquid processor (Newtown, CT) at 20% amplitude with a 1-s-on and 1-s-off duty cycle for 2
min. The primary emulsion was poured into 20 mL 1% PVA aqueous solution and homogenized
for 3 min with 5,000 rpm. The remaining preparation steps were the same as the preparation of
PW NPs.
PLGA/Eudragit E100/WR12 (PEW) NP. PEW NPs were prepared by the O/W single
emulsion solvent evaporation technique. The organic phase was prepared by dissolving PLGA in
DCM together with different ratio of Eudragit E100 (PLGA: E100, from 15: 5 to 18: 2), followed
by the addition of 400 μL DMSO containing 2 mg WR12. The organic phase was emulsified in
the 20 mL 1% PVA polymer solution through homogenization for 3 min at 5,000 rpm. The
following procedures were processed in the same manner as PW NPs.
PLGA/Eudragit (PE) NP. For comparison, NPs composed of PLGA and E100 with
different ratios were prepared in the same way as PEW NPs except for omitting WR12.
2.2.6 Determination of drug loading
The WR12 content in the NPs was analyzed by high pressure liquid chromatography
(HPLC). To determine the drug loading, 2 mg of NPs were dissolved in 0.5 mL of DMSO and
treated with 1.5 mL of 10 mM phosphate buffer (pH 3) to induce polymer precipitation. The
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resulting suspension was centrifuged at 12,126 rcf for 20 min to separate supernatant and pellets.
WR12 content in the supernatant was analyzed by HPLC. The drug loading (%) was defined as
the weight of drug in the NPs divided by the weight of NPs.
2.2.7 In vitro drug release profiles
The rate of WR12 release from the NP was observed in the PBS (pH 7.4) solution,
acetate buffered saline (pH 5) or phosphate buffered saline (pH 3). The NP suspensions were
divided to 1.8 mL aliquots and incubated at 37 °C with continues agitation. After 1, 2, 4, 8, 12,
and 24 h, an aliquot was taken out and centrifuged at 12,126 rcf for 20 min, and the amount of
released WR12 in the supernatant was measured by HPLC.
2.2.8 Cytotoxicity test
J774a.1 macrophages were seeded at a density of 1 ×104 cells per well in a 96-well tissue
culture plate in DMEM medium containing 10% FBS. The cells were incubated for 3 h with
various concentrations of NPs or free drug at 37 °C in a 5% CO2 atmosphere. The cell viability
was measured by the MTT assay. Cells were treated with 75 μg of MTT and incubated for 4 h.
The formazan crystal was solubilized in the stop/solubilization solution (50% DMF, 20%
DMSO, pH 5) and measured by a SpectraMax M3 microplate reader (Molecular Devices, CA) at
a wavelength of 562 nm.
2.2.9 Intracellular antibacterial efficacy (with the courtesy of Dr. Mohamed F. Mohamed in
Seleem Lab)
J774a.1 cells were seeded at a density of 1.5 × 104 per well in a tissue culture 96-well
plate in DMEM medium supplemented with 10% fetal bovine serum (FBS), and incubated at
37°C in a 5% CO2 atmosphere for 36 hours (till 95 % confluence). Following incubation, the
cells were washed once with DMEM medium, followed by the infection with L. monocytogenes
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or Salmonella Typhimurium in complete medium (DMEM with 10% FBS) for 1 hr. After
infection, the wells were washed three times with 200 µl medium with gentamicin (final
concentration 50 μg/ml). Subsequently, cells were washed with fresh medium and then incubated
with free drug or nanoparticles for specific time points. Ampicillin or ciprofloxacin was used as
positive control. After incubation, cells were washed twice with PBS. One hundred microliters of
PBS with 0.01% Triton X was added to each well to lyse the macrophages. Next, 100 µL of PBS
containing 0.01% Triton X-100 was added to lyse cells. Subsequently, bacteria were diluted and
plated on TSA plates. Plates were incubated at 37 ºC for 24 h. Bacteria were counted, and colony
forming units (CFU) were calculated.

2.3

Results and discussion

2.3.1 ZWC synthesis and characterization
Zwitterionic chitosan with different anhydride/amine (An/Am) ratios were synthesized by
partial succinylation of primary amines in the chitosan. Two ZWCs (ZWC0.7 and ZWC0.3) were
synthesized. ZWC0.7 refers to a theoretical An/Am ratio of 0.7, and ZWC0.3 refers to a ratio of
0.3. The actual degree of succinylation was determined by 1H-NMR spectrum (Fig. 5). The
appearance of a new peak at 2.5-2.7 ppm indicates the advent of four protons of two methylenes
after succinylation. Initially, methine protons next to the primary amine (position b) have a
chemical shift of 3.1 – 3.3 ppm. After succinylation, it was downshifted to 3.5-3.7 ppm [17].
Thus, the degree of the succinylation was calculated by the following equation. The actual
degree of succinylation was 55% for ZWC0.7 and 30% for ZWC0.3.
𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑜𝑓 𝑝𝑒𝑎𝑘 𝐴

Degree of succinylation = (𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑜𝑓 𝑝𝑒𝑎𝑘 𝐴)+4 ×(𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑜𝑓 𝑝𝑒𝑎𝑘 𝐵) ×100%
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Figure 5. Synthesis and characterization of ZWC. (a) Schematic of ZWC synthesis. b) 1H NMR
spectra of unmodified chitosan, ZWC0.3 and ZWC0.7. The materials were dissolved in 2%
CD3COOD in D2O at 70 °C. The methylene protons in the succinyl group (a’, a) appeared as a
new peak at 2.5-2.7 ppm, whereas the methine proton at position b was responsible for the peak
at 3.1-3.3 ppm.

2.3.2 ZWC showed a pH dependent charge profile
Zeta potential of unmodified chitosan and ZWCs were evaluated at different pH (Fig. 6).
ZWC showed negative charges at relatively base pHs and positive charges at acidic pHs. The pH
at which the charge changes (isoelectric point, pI) depended on the degree of succinylation in
ZWC. ZWC0.7 with a higher succinylation degree showed a lower pI (4.4) than ZWC0.3 (pI: 6.6),
which is consistent with our previous report [18].
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Figure 6. Zeta potential (a) and turbidity (b) of unmodified chitosan, ZWC0.7 and ZWC0.3 at
different pH.

2.3.3 Formation of ZWC/CAMP complex
The net charge of WR12 and RRIKA was +12.6 ± 0.95 mV and +6.4 ± 0.05 mV,
respectively. Upon adding ZWC0.7 to the CAMPs (WR12 or RRIKA), the mixture became
turbid and the derived count rate increased substantially, indicating the formation of complex.
These complexes were formed by the electrostatic attraction of negatively charged ZWC0.7 and
positively charged CAMPs at physiological pH. Compared to ZWC0.7, ZWC0.3 possess less
charge density and it only formed complex with WR12, which has a higher charge density. The
particle size, polydispersity index (PDI) and derived count rate for each pair were summarized in
Table 2. When the pH was adjusted to an acidic range, the turbidity and derived count rate were
reduced (Fig. 7), indicating the dissociation of the complex. Given that ZWC flips the charge
from negative to positive at a pH below its pI value, the complex dissociation is likely due to the
electrostatic repulsion of ZWC and CAMPs.
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Table 2. Particle size, polydispersity index (PDI), and derived count rate of ZWC/CAMP NPs.
Sample name
ZWC0.7

Particle size
(diameter, nm)
328.1 ± 35.7

Polydispersity index
(PDI)
0.63 ± 0.06

Derived count rate
(kcps)
72.4 ± 8

ZWC0.3

528.7 ± 50.6

0.77 ± 0.10

166.9 ± 1

WR12

2268 ± 355

0.36 ± 0.07

1705.7 ± 562.4

RRIKA

656.7 ± 32.9

0.35 ± 0.02

33.1 ± 0.5

ZWC0.7/WR12

636.6 ± 2.4

0.42 ± 0.06

5684.8 ± 62.4

ZWC0.3/WR12

329.7 ± 11.9

0.39 ± 0.05

3036.6 ± 38.2

ZWC0.7/RRIKA

433.2 ± 8.6

0.43 ± 0.06

2789.2 ± 34.8

ZWC0.3/RRIKA

307.4 ± 14.9

0.42 ± 0.01

190 ± 0.6

2.3.4 Stability of ZWC/CAMP complex
To study the stability in biological milieu, ZWC/CAMP complexes were challenged with
sodium chloride (154 mM) and human serum albumin (50 mg/mL), mimicking the ion and
protein contents in the blood (Fig. 8). The derived count rate of ZWC/CAMP complex was
decreased after the challenge, indicating the dissociation of the complex. The ZWC0.7/WR12
complex was relatively more stable than the ZWC0.7/RRIKA or ZWC0.3/WR12, probably due to
the higher electrostatic force formed between ZWC0.7 and WR12, which possess higher charge
density than the other counterpart, ZWC0.3 and RRIKA, respectively. Although ZWC is a
promising pH sensitive material to form NPs with CAMPs for their systemic delivery, the
stability of complex remains to be improved.
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Figure 7. Dissociation of ZWC/WR12 complex at acidic pH, evidenced by the decrease of
turbidity (left column) and derived count rate (right column) at acidic pH.

Figure 8. Stability of ZWC/CAMP complex at sodium chloride (154mM) and albumins (50
mg/mL).
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2.3.5 Stability enhancement by crosslinked ZWC-SH/CAMP complex
To enhance the stability, we synthesized thiolated ZWC0.7 (ZWC-SH) and complexed
with WR12 or RRIKA (Table 3). According to the analysis by Ellman’s reagent, the degree of
thiolation was 17.9 ± 2.0 % (n = 2), indicating 17.9 mol% of primary amines in the ZWC0.7 were
replaced by thiol groups. The thiol groups in the ZWC-SH can form crosslinked disulfide bond
with other thiols upon oxidization, strengthening the physical interaction of ZWC-SH/CAMP.
The derived count rate of ZWC-SH/CAMP remained stable at sodium chloride (154 mM) and
maintained 70% at human serum albumin (50 mg/mL) (Fig. 9), which contrast with the previous
ZWC/CAMP. This indicates that thiol crosslinking can enhance the stability of ZWC-SH/CAMP
at physiological media.
Table 3. Particle size, polydispersity index, and derived count rate of ZWC-SH/CAMP NPs
Sample name
ZWC-SH0.7

Particle size
(diameter, nm)
108.3 ± 35.7

Polydispersity index
(PDI)
1±0

Derived count rate
(kcps)
23.1 ± 0.8

WR12
RRIKA
ZWC-SH0.7/WR12

2268 ± 355
656.7 ± 32.9
770.1 ± 85.9

0.36 ± 0.07
0.35 ± 0.02
0.59 ± 0.09

1705.7 ± 562.4
33.1 ± 0.5
8081.3 ± 589.8

Figure 9. Stability of ZWC-SH/CAMP complex at sodium chloride (154mM) and albumins (50
mg/mL).
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2.3.6 Intracellular antibacterial activity of ZWC/CAMP and ZWC-SH/CAMP
The antibacterial activities of ZWC/CAMP and ZWC-SH/CAMP complexes were tested
against Listeria and Salmonella resided inside J774a.1 macrophages (Fig. 10 & 11).
Unfortunately, no antimicrobial activity was observed for all tested formulations. Although
crosslinking helps enhance the stability of the complex, the complex may still have dissociated in
the complete medium prior to the macrophage uptake. Since the complex alone is unlikely to
survive in the circulation due to low stability, additional efforts were made to ensure stable drug
retention in the NPs.

Figure 10. Intracellular antimicrobial activity of ZWC/CAMPs against macrophage-resident
listeria and salmonella. The macrophages were incubated with treatments (50 µg/mL CAMP
equivalent) for 10 h. Ampicillin or ciprofloxacin was used as positive control. With the courtesy
of Dr. Mohamed F. Mohamed.
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Figure 11. Intracellular antimicrobial activity of ZWC-SH/CAMPs against macrophage-resident
bacteria. (a) Listeria. (b) Salmonella. (c) Cytotoxicity of individual drugs and ZWC-SH/CAMPs
against J774a.1 macrophages. The macrophages were incubated with treatments (75 or 150
µg/mL CAMP equivalence) for 9 h. Ampicillin was used as positive control. With the courtesy
of Dr. Mohamed F. Mohamed.
2.3.7 WR12 encapsulation in PLGA
To enhance the stability of the particles at physiological condition, PLGA was used as the
main platform to encapsulate WR12, and ZWC was included in the PLGA particles as the pHsensitive material to trigger WR12 release at acidic pH. The formulation, yield, hydrodynamic
diameter, and drug loading of different NPs were summarized in the Table 4.
When WR12 was encapsulated in PLGA via the O/W single emulsion method, the drug
loading achieved 9.95 %. PLGA/WR12 NPs was tested against intracellular Brucella and
Salmonella; however, it did not decrease the intracellular bacteria counts (Fig. 12).
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Table 4. WR12 encapsulation in NPs with different polymer composition.

PW
PZW
PEW
PEW

PLGA ZWC0.3 E100 WR12 Z-average
(mg)
(mg)
(mg) (mg)
(nm)
20
2
826 ± 23
20
4
2
1065 ± 147
15
5
2
850 ± 31
18
1
2
750 ± 61

Drug loading
(%)
9.95 ± 2.60
8.70 ± 2.25
11.53
8.45

Figure 12. Intracellular antimicrobial activity of PLGA/WR12 against macrophage-resident
Brucella and Salmonella. The macrophages were incubated with treatment (71 µg/mL CAMP
equivalence) for 17 h. Ciprofloxacin was used as positive control.

With additional ZWC, the drug loading decreased to 8.70%. The decreased drug loading
may be explained from the morphology of the particles. PZW and PW NPs were observed with
scanning electron microscopy (SEM). Both NPs were spherical but showed slightly different
surfaces (Fig. 13). The surface of PW NPs appeared smooth, while PZW NPs had tiny pores on
the surface, which is a typical appearance of PLGA NPs prepared by the double emulsion
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method. When hydrated, the pores of PZW NPs may have served as small water channels and
caused drug loss during particle fabrication.

Figure 13. SEM images of PZW0.3 and PW NPs.
The drug release was tested at pH 7.4 and pH 3.0 buffered saline. Neither PW nor PZW
showed drug release at pH 7.4 buffered saline (Fig. 14a), indicating that PLGA can hold the drug
inside its matrix at physiological pH. In an acidic buffer (pH 3), more than 90% of WR12 was
released from PZW in 24 h whereas only a partial release of WR12 (38%) was observed from
PW. This indicates that ZWC in PZW NPs induced the release of WR12 at acidic pH, where the
protonated ZWC repelled cationic WR12 to trigger its release from the PLGA matrix. However,
PZW did not enhance drug release at lysosomal pH (pH 5). We suspect the electrostatic
repulsion between ZWC and WR12 at pH 5 was not strong enough to trigger W12 release from
the PLGA matrix. That indicates that even if the NPs are delivered to the macrophages, the drug
will not be released from NPs and unable to interact with intracellular bacteria. Recognizing this
limitation, we investigated alternative pH-sensitive materials which can help release the drug at
lysosomal pH from PLGA matrix.
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Figure 14. Release kinetics of WR12 from PLGA NPs. (a) WR12 release (%) from PW and PZW
NPs at pH 7.4 and 5. PW pH7.4 was overlapped with PZW pH7.4. (b) WR12 release from PEW
(15:5:2) NPs.

2.3.8 Eudragit E100 induces the release of cationic peptides when encapsulated in PLGA NPs
In order to make the NPs pH-sensitive enough to release the drug at pH 5, ZWC was
replaced with Eudragit E100, a cationic copolymer with acid-dependent water-solubility (not
soluble at pH > 5). Eudragit E100 was mixed with PLGA in various ratios to form PEW NPs by
the single emulsion solvent evaporation method. The particle size and drug loading were
summarized in Table 4. PEW showed pH-sensitive drug release: No WR12 was observed from
PEW (15:5:2) NPs at pH 7.4, whereas >40% of the drugs were released in 48 h in pH 5 medium
(Fig. 14b).
2.3.9 Intracellular WR12 had toxicity to macrophages
Toxicity of PEW against J774a.1 macrophages was evaluated by the MTT assay. PEW
NPs prepared at a ratio of 15:5:2 (Fig. 15a) showed significant cytotoxicity to the J774a.1
macrophages. The toxicity was slightly reduced as the E100 content was reduced (18:2:2). To
examine where the toxicity comes from, NPs were prepared omitting each component: PE
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(without WR12) or PW (without E100). PW was not toxic at all concentrations, but PE was
slightly toxic (Fig. 15a). This indicates that E100 was mainly responsible for the cytotoxicity
and its use should be limited to the minimum.

Figure 15. Cytotoxicity of NPs against J774a.1 macrophages. (a) The cytotoxicity of NPs
composed of different polymer composition were compared. (b) Cytotoxicity comparison of
PEW vs. PW NPs at different concentration. (c) Cytotoxicity of free WR12.
2.3.10 Indirect evidence of intracellular delivery of WR12 to macrophages by PEW
In Fig. 15a, it is noteworthy that PEW (18:2:2) and PE (20:1) showed significant
difference in cytotoxicity. The difference might be explained by the E100 content (2/22 = 9.1%
for PEW; 1/21 = 4.8% for PE), but the role of WR12 could not be completely ruled out.
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Therefore, PEW with a comparable E100 content (4.8%) was prepared and compared with PE.
Interestingly, PEW showed greater toxicity than PE with a comparable level of E100 (Fig. 15b).
Given that WR12 content in PEW was no higher than 9.5%, the WR12 concentration provided as
PEW would have been at most 48 μg/mL. However, free WR12 showed minimal toxicity at a
concentration of 50 μg/mL or lower (Fig. 15c). This indicates that the relatively high toxicity of
PEW compared to PE is due to the WR12 delivered into the cells via PEW. It is worthy to note
that PW was not toxic at all (Fig. 15a) even though PW also entered cells. The difference
between PW (Fig. 15a) and PEW (Fig. 15b) is likely due to the differential intracellular release
of WR12 (Fig. 14).

2.4

Conclusion
WR12 and RRIKA are cationic antimicrobial peptides active against planktonic bacteria but

do not kill intracellular bacteria because they do not enter macrophages due to the large size.
Zwitterionic chitosan (ZWC) with a pH-dependent charge profile was synthesized as a carrier to
deliver CAMPs to the intracellular pathogens. The studies with two CAMPs (WR12 and
RRIKA) showed that the CAMPs formed complexes with ZWC at pH 7.4 and dissociated from
ZWC at acidic pH. However, the complex was unstable at the physiological pH in the presence
of ions and proteins. Encapsulation in PLGA NPs improved the stability of the ZWC/WR12
complex; however, the NPs (PZW) released WR12 only at pH 3 but not at lysosomal pH 5. In
order to enhance the pH-sensitivity, ZWC was replaced by acid-soluble polymethacrylate
Eudragit E100. The PEW NPs showed significant release of drugs at pH 5 and none or minimal
release at pH 7.4. However, due to the toxicity resulting from intracellular release of E100 and
WR12, PEW was no longer pursued. In subsequent studies, WR12 was replaced with
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vancomycin (Chapters 3 and 4), and a new encapsulation method excluding E100 was explored
(Chapter 5).
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ENGINEERING VANCOMYCIN-LOADED
NANOPARTICLES FOR TREATING INTRACELLULAR MRSA
INFECTION

3.1

Introduction
Bacterial resistance has been identified in every geographic region of the world and

posed a significant global public health challenge [1]. Annually, in the United States alone,
multidrug resistance pathogens negatively impact the lives of over two million patients at a cost
of $20 billion to the healthcare system and result in over 23,000 deaths [2]. Half of these
fatalities are attributed to a single bacterial pathogen, methicillin-resistant Staphylococcus aureus
(MRSA) [3]. S. aureus can invade and survive in mammalian host cells [4]. Within these safe
havens, S. aureus reproduces and forms a repository, often causing chronic and recurrent
infections. Infected patients become life-long carriers, chronically suffering from the infection,
or die from invasive forms of the disease [5-9]. This suggest that eradicating intracellular S.
aureus is the key to clinical success; however, treatment with conventional antimicrobials during
the S. aureus intracellular invasion phase is a daunting task [4]. Most antimicrobials are unable
to access infected host cells and achieve the optimal therapeutic concentrations within the
intracellular replicative niches. As such, the therapeutic value of vancomycin (drug of choice for
treatment of MRSA) is often limited, and clinical failures are common in intracellular MRSA
infections [9-12]. This high failure rate, which exceeds 40%, is mainly attributed to poor
intracellular penetration of the drug [4, 9-12].

_____________________________________________

The content of this chapter is reprinted with permission from “Particle engineering for intracellular delivery of
vancomycin to methicillin-resistant Staphylococcus aureus (MRSA)-infected macrophages” by Pei, Y.,
Mohamed, M., Seleem, M. and Yeo, Y., 2017. J Control Release, 267:133-143. Copyright (2017) Elsevier.
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One way to overcome poor intracellular delivery of vancomycin is to encapsulate the
drug in particulate formulations and take advantage of the inherent ability of phagocytes to
internalize the particles. Several studies have used liposomal nanoparticles (NPs) for the delivery
of vancomycin to macrophages [13-16]. However, the liposome formulations generally suffer
from low drug encapsulation efficiency (drug entrapped/drug added, <20%) [14-17]. Polymeric
NPs based on poly(lactic-co-glycolic acid) (PLGA) or chitosan have also been used to
encapsulate vancomycin, but they can only afford 4-6 wt% loading efficiency (drug/NPs) due to
the high hydrophilicity of the drug [18, 19]. Both cases are undesirable: the low encapsulation
efficiency increases the production cost, and the low drug loading necessitates the administration
of a large quantity of excipients, which can possess undesirable biological activities. Moreover,
the high fraction of carrier components increases the concentration of NPs, which may cause
aggregation of the particles.
In the present study, we aim to develop a polymeric particle formulation that can
efficiently encapsulate and deliver vancomycin to intracellular pathogens. The particle
formulation consists of polymers with distinct functions: poly(lactic-co-glycolic acid) (PLGA),
polyethylene glycol-PLGA conjugate (PEG-PLGA), Eudragit E100 (E100, a copolymer
consisting of dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate at a
ratio of 2:1:1), and a chitosan derivative with a pH sensitive charge profile (Fig. 16). PLGA
serves as the main delivery platform as a biodegradable and biocompatible polymer [20], in
which the inclusion of PEG-PLGA helps maintain an appropriate level of polarity for timely
release of vancomycin. E100, a cationic copolymer soluble at < pH 5 [21], is used to enhance
vancomycin encapsulation. E100 is typically used in oral dosage forms for taste masking and
transdermal patches for mucoadhesion [21, 22]. In the current formulation, E100 is blended as a

65
minor fraction of polymer matrix to retain the drug via non-covalent interactions. Finally, a
chitosan derivative we previously developed [23], called zwitterionic chitosan (ZWC), is
included to trigger the drug release after cellular uptake of the particles. ZWC is negatively
charged at pH 7.4 but positively charged in weakly acidic environment. ZWC is thus expected to
neutralize the cationic charge of E100 at physiological pH to mitigate potential toxicity but
enhance the drug release in acidic milieu via electrostatic repulsion of E100-bound vancomycin.
The NPs are produced in the range of 500-1000 nm to promote preferential uptake by
macrophages while avoiding embolism [24, 25].

Figure 16. Chemical structures of NP components.
On the basis of the size and the interplay between the components, we hypothesize that
the particles will readily be phagocytosed by macrophages, release vancomycin in the acidity of
endo/lysozymes, and effectively kill intracellular pathogens. Here, we produce and characterize
multi-component NPs with high capacity to encapsulate vancomycin and test their anti-microbial
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activities against different strains of Gram-positive clinical isolates resident in macrophages. NPs
prove to be a unique delivery platform of vancomycin, which is superior to free vancomycin in
reducing intracellular pathogens.

3.2

Materials and Methods

3.2.1 Materials
Vancomycin hydrochloride, ninhydrin, hydrindantin, succinic anhydride, fetal bovine
serum (FBS) and Mueller-Hinton broth (MHB) were purchased from Sigma-Aldrich (St. Louis,
MO. PLGA (50:50 LA:GA, 0.15-0.25 dL/g, acid-terminated) was purchased from LACTEL®
(Denver, CO). Methoxy PEG-PLGA (PEG-PLGA, PEG- 5kDa, PLGA 50:50 LA:GA 4 kDa) and
RhoB-PLGA (LA:GA 50:50, ester-terminated, 30 kDa) were purchased from Akina, Inc. (West
Lafayette, IN). Eudragit E100 was a gift from Evonik (Darmstadt, Germany). Ethanol,
dichloromethane (DCM), and acetonitrile (ACN) were purchased from Fisher Scientific
(Hampton, NH). Hoechst 33342, BODIPY-vancomycin conjugate, 1,1'-Dioctadecyl-3,3,3',3'Tetramethylindotricarbocyanine Iodide (DiR), and Dulbecco's Modified Eagle's medium
(DMEM) were purchased from Life Technology (Carlsbad, CA). Triton X-100 was purchased
from Bio-Rad (Hercules, CA). MTS reagent was purchased from Promega (Madison, WI).
Trypticase soy broth (TSB) and Trypticase soy agar (TSA) were purchased from BectonDickinson (Cockeysville, MD). Deionized (DI) water was obtained from a Milli-Q ultrafiltration
system (Millipore, Bellerica, MA).
3.2.2 PpZEV NP Preparation
The PpZEV NPs were prepared by the water-oil-water (w1/o/w2) double emulsion
solvent evaporation method. First, 3 mg of vancomycin hydrochloride was dissolved in 0.2 mL
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of DI water and neutralized with 15 μL of 0.1N NaOH. Eight milligrams of ZWC was dissolved
in 0.8 mL of DI water and combined with the vancomycin solution to make 1 mL of internal
water phase (w1). Next, organic phase was prepared by dissolving 10 mg of PLGA, 10 mg of
PEG-PLGA, and 1.5 mg of E100 in 4 mL of DCM. The primary emulsion (w1/o) was formed by
mixing the w1 phase and the organic phase with a SONICS® Vibra-Cell ultrasonic liquid
processor (Newtown, CT) at 25% amplitude with a 1-s-on and 1-s-off duty cycle for 4 min. The
w1/o primary emulsion was then emulsified in 20 mL of 1% PVA solution (w2) with a
Silverson® homogenizer (East Longmeadow, MA) at 5,000 rpm for 3 min to form a w1/o/w2
double emulsion. The double emulsion was added to 40 mL of DI water and stirred for 30 min.
All the aqueous phases were neutralized with 0.1N NaOH. The residual DCM was removed by
rotary evaporation for 30 min. The NPs were collected by centrifugation at 8,891 rcf for 15 min,
washed with DI water twice, lyophilized with a Labconco freeze-dryer (Kansas City, MO), and
stored at -20 °C.
For comparison, PZV, PpZV, and PZEV NPs were prepared in the same way as PpZEV
NPs omitting E100 and/or PEG-PLGA. Particles without ZWC (PV, PEV and PpEV NPs) were
prepared by adding 0.2 mL of neutralized vancomycin solution to 2 mL of DCM containing
polymer(s) (PLGA, PEG-PLGA, and/or E100), sonicating the mixture for 2.5 min, and
processing the rest in the same manner as PpZEV NPs.
For confocal microscopy, fluorescently labeled PpZEV NPs were prepared with
rhodamine B-labeled PLGA (RhoB-PLGA) and/or BODIPY-conjugated vancomycin (BODIPYvancomycin). When PLGA was labeled, 20% of PLGA was replaced with RhoB-PLGA, and the
NPs were named P*pZEV. For vancomycin labeling, 2.5% of vancomycin was replaced with
BODIPY-vancomycin, and the NPs were named PpZEV*. When both PLGA and vancomycin
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were labeled, the NPs were called P*pZEV*. For whole body fluorescence imaging, DiR labeled
PpZEV NPs were prepared by adding 100 μg DiR to the organic phase while keeping the rest
procedure the same.
3.2.3 PpZEV NP characterization
The hydrodynamic diameter and zeta potential of NPs were measured by dynamic light
scattering (DLS) using a Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK). For
the size measurement, NPs were dispersed in DI water at a concentration of 1.5 mg/mL. The zeta
potential of NPs was measured at different pHs with the NPs suspended in phosphate buffer (5
mM, pH 7.4) or acetate buffer (5 mM, pH 5). NPs were imaged with a FEI NOVA nanoSEM
scanning electron microscope (SEM).
To determine the vancomycin loading, 1 mg of NPs were dissolved in 0.5 mL of DMSO
and treated with the same volume of DI water to induce polymer precipitation. The suspension
was centrifuged at 12,126 rcf for 20 min to separate a supernatant, which was analyzed by high
pressure liquid chromatography (HPLC). The drug loading was defined as the mass of
encapsulated vancomycin divided by the mass of NPs. The ZWC content in PpZEV NPs was
determined by the ninhydrin assay [26, 27]. In short, a ninhydrin reagent was freshly prepared by
dissolving 400 mg ninhydrin and 60 mg hydrindantin in a mixture of DMSO (15 mL) and 4 M
lithium acetate buffer (5 mL). Aqueous NP suspension was mixed with the ninhydrin reagent in
an equal volume ratio and heated to 100 °C for 20 min, cooled and quenched with 0.5 mL
ethanol. The absorbance of the mixture was measured at 570 nm with a SpectraMax M3
microplate reader (Molecular Device, Sunnyvale, CA). The ZWC content in PpZEV NPs was
estimated using a calibration curve plotted with ZWC of known concentrations after subtracting
the basal level of absorbance due to vancomycin alone.
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3.2.4 In vitro vancomycin release
For the estimation of extracellular and intracellular vancomycin release, NPs were
suspended in PBS (pH 7.4) and acetate buffered saline (pH 5), respectively, and incubated at 37
°C with constant agitation. After 1 h, the suspension was centrifuged at 12,126 rcf for 20 min at
room temperature (RT), and the supernatant was analyzed with HPLC. The incubation was
performed for 1 h to compare the sensitivity of NPs to pH change. To view NPs in each pHs,
NPs were incubated for 4 h, collected by centrifugation at 12,126 rcf for 20 min at RT, washed
with DI water, lyophilized, and imaged with SEM. The NPs for imaging were left in each
medium longer than the release kinetics (4 h vs. 1 h) to maximize the difference between NPs in
each pH and facilitate the visual inspection. The SEM images of randomly selected 10-15 NPs
were analyzed with Fiji image analysis software (US National Institute of Health, Bethesda, MD)
to determine the percentage of pore area on each NP surface. Specifically, pores in each particle
were identified by visual inspection according to the contrast difference (pore area is darker) and
the edge was marked with yellow dotted line manually (Supporting Fig. 4). Similarly, white
dotted line was applied to the whole particle boundary to represent particle area (Supporting Fig.
4). The percentage of pore area on each NP surface was estimated by dividing the area of particle
(area under white dotted line) by the sum of pore area (area under yellow dotted line).
3.2.5 Interaction of vancomycin and Eudragit E100
Vancomycin-encapsulated Eudragit E100 (EV) NPs were prepared by the double
emulsion solvent evaporation method. Five milligrams of vancomycin was dissolved in 0.2 mL
of DI water neutralized with 10 μL of 0.1N NaOH, added to 1 mL of DCM solution containing
20 mg E100, and mixed by sonication at 30% amplitude with a 1-s-on and 1-s-off duty cycle for
3 min. The primary emulsion was further emulsified in 5 mL of 1% PVA solution. The double
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emulsion was added to 20 mL of DI water and stirred for 30 min, followed by 30 min rotary
evaporation. The EV NPs were collected by centrifugation at 43,400 rcf for 15 min and washed
with DI water twice. The collected NPs were dispersed in DI water and stored at 4 °C. To
determine the vancomycin loading, EV NPs were dissolved in ethanol and mixed with the same
volume of water to separate the precipitated polymer. After centrifugation at 12,126 rcf for 20
min, vancomycin in the supernatant was analyzed with HPLC. To determine the nature of E100vancomycin interaction, EV NPs were incubated in 1.54 M NaCl or 5 M urea solution at RT for
2 h with constant agitation, and the released vancomycin was determined with HPLC.
3.2.6 HPLC analysis of vancomycin
HPLC analysis of vancomycin was performed with an Agilent 1100 HPLC system and a
Phenomenex Luna 5 μm C18(2) column (100 Å, 250 × 4.6 mm) with a column temperature of
40°C. The mobile phase was a mixture of solvent A (0.05% Trifluoroacetic acid (TFA) in
acetonitrile) and solvent B (0.05% TFA in water) and flowed at 0.7 mL/min. Initially, the
column was equilibrated with a mobile phase consisting of 10% solvent A and 90% solvent B for
3 min. A linear gradient was then applied, increasing solvent A from 10% to 100% over 8 min.
Subsequently, the column was eluted with 100 % solvent A for 5 min, and the mobile phase was
returned to the initial condition and re-equilibrated, making the total analysis time 22 min.
Vancomycin was detected at 280 nm.
3.2.7 Macrophage uptake of PpZEV NPs
The uptake of PpZEV NPs by J774A.1 macrophages was observed with a Nikon A1R
confocal microscope equipped with a Spectra Physics 163C argon ion laser and a Coherent
CUBE diode laser (Nikon America Inc., NY, USA). J774A.1 macrophages were cultured in
Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS, 100 units/mL
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penicillin, and 100 μg/mL streptomycin. The macrophages were seeded in a 35 mm glassbottomed confocal dish (MatTek, Ashland, MA) at a density of 5×105 cells and incubated
overnight at 37°C in a humidified 5% CO2 atmosphere. Optionally, J774A.1 cells were infected
with MRSA (multiplicity of infection, 100:1) in DMEM containing 10% FBS for 1 h. After
infection, the wells were washed twice with medium containing 50 µg/mL gentamicin to remove
extracellular MRSA.
The cells were incubated in a 50 μg/mL suspension of fluorescently labeled PpZEV NPs
in complete medium. After 3 h incubation, the cells were washed with fresh medium twice to
remove free or loosely bound NPs and stained with Hoechst 33342 to label the nuclei. The
fluorescent NPs were excited at 488 nm (λem: 500-550 nm, for BODIPY-vancomycin detection)
and/or at 561 nm (λem: 570-620 nm, for RhoB-PLGA detection). Another set of cells was
imaged after additional 21 h incubation in NP-free fresh medium. The fluorescence intensity was
quantified by the Fiji image analysis software.
3.2.8 Confocal microscopy of fluorescently labeled PpZEV NPs at different pHs
Dual-labeled P*pZEV* NPs were incubated in either PBS (pH 7.4) or acetate buffered
saline (pH 5) and incubated at 37 °C with constant agitation. After 1 h, the suspension was
centrifuged at 12,126 rcf for 20 min. The collected pellets were re-dispersed in DI water,
mounted on a cover slip with Clearmount (Zymed, San Francisco, CA), and imaged with
confocal microscopy.
3.2.9 Determination of vancomycin in macrophages
J774A.1 macrophages were plated in a 6-well plate at a density of 106 cells per well with
2 mL of complete medium. After 24 h incubation, the medium was replaced with 2 mL of fresh
complete medium containing 50 μg/mL PpZEV NPs or free vancomycin (both equivalent to 4.35
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µg/mL vancomycin). After 24 h incubation, cells were washed with PBS once, detached from the
plate with a cell scraper. Cells from 6 wells were pooled, counted and collected by centrifugation
at 233 rcf for 3 min. The cell pellets were suspended in pH 5 buffered saline containing 0.1%
Triton X for 1 h at RT with agitation to recover the total vancomycin in the cells. The samples
were treated with 5 M urea to disrupt vancomycin binding to cellular proteins and centrifuged at
4950 rcf for 5 min to separate a supernatant (containing vancomycin and soluble proteins). The
proteins in the supernatant were precipitated with the same volume of saturated ammonium
sulfate and removed by 15 min centrifugation at 12,126 rcf. The supernatant was analyzed with
HPLC, and the vancomycin concentration in the cell was estimated by the following equation.
Here, the volume of a single macrophage is considered to be 3.95 × 10-10 mL according to the
literature [28].
Total vancomycin recovery from cells (μg)

Vancomycin concentration in the cells (μg/mL) = Cell number ×(3.95  10−10 mL) (per cell volume)
3.2.10 Cytotoxicity studies
PpZEV NPs were examined with respect to in vitro toxicity against J774A.1
macrophages as described before [29]. Briefly, cells were seeded at a density of 1.5 × 104 per
well in a 96-well tissue culture plate in DMEM containing 10% FBS and incubated at 37 °C in a
5% CO2 atmosphere for 24 h. The cells were treated with PpZEV NPs at different concentrations
for 24 h. The cells were then washed and incubated with 100 µL of DMEM containing 20 µL of
MTS reagent for 4 h at 37 ºC. Corrected absorbance readings were taken using a microplate
reader (Molecular Devices, Sunnyvale, CA, USA).
3.2.11 Intracellular antimicrobial activities
To assess the antimicrobial activity of PpZEV NPs against intracellular bacteria, J774A.1
cells were infected with different bacteria as described in previous studies [30, 31] and treated
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with PpZEV NPs. Briefly, J774A.1 cells were seeded and incubated as described in Section 2.10.
Following the incubation, cells were infected with MRSA, Listeria monocytogenes,
Enterococcus fecalis, Enterococcus faecium or Streptococcus pneumoniae (multiplicity of
infection, 100:1) in DMEM containing 10% FBS for 1 h. After infection, the wells were washed
with 200 µL medium containing 50 µg/mL gentamicin and further incubated for 30 min with
gentamicin to kill remaining extracellular bacteria. NPs and free vancomycin were diluted to the
desired concentrations with DMEM containing 10% FBS and 5 µg/mL gentamicin and added to
the wells. After 24 h incubation, the treatments were removed, and the wells washed twice with
PBS to remove residual test agents. Next, 100 µL of PBS containing 0.01% triton X-100 was
added to lyse cells. Subsequently, bacteria were diluted and plated on TSA plates or blood agar
plates (S. pneumoniae). Plates were incubated at 37 ºC for 16 h. Bacteria were counted, and
colony forming units were calculated.
3.2.12 Distribution of PpZEV NPs in mice
All animal procedures were approved by Purdue Animal Care and Use Committee, in
conformity with the NIH guidelines for the care and use of laboratory animals. 5-6 weeks old
female BALB/c mice were purchased from Envigo (Indianapolis, IN) and acclimatized for 1
week. The hair of the animals was removed with a hair removal lotion one day before NP
treatment. Animals received a tail-vein injection of 0.2 mL of NP suspension containing 0.192
mg PpZEV NPs loaded with DiR (n = 3). Whole body fluorescent images were acquired at 10
min, 30 min, 1, 3, 9, 24 and 96 h post-injection under 3% isoflurane anesthesia using an AMI
whole animal imager (Spectral Instruments, Tucson, Az) with an excitation and emission
wavelength of 745 nm and 790 nm, respectively. Another group of animals (n = 3) received the
same treatment and sacrificed at 3 h post-injection. Major organs were collected from the
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sacrificed animals and imaged ex vivo by the AMI imager. The fluorescence intensity of each
organ was quantified by the AMI viewer image software (Spectral Instruments, Tucson, Az).
3.2.13 Statistical analysis
All statistical analysis was performed with GraphPad Prism 7 (La Jolla, CA). All data were
analyzed with unpaired two-way t-test or one-way or two-way ANOVA test to determine the
difference of means among groups, followed by the recommended multiple comparisons test
such as Dunnett’s, Sidak’s, and Tukey’s multiple comparisons tests. A value of p < 0.05 was
considered statistically significant.

3.3

Results and Discussion

3.3.1 Eudragit E100 facilitates vancomycin encapsulation in PLGA NPs
The formulation, yield, and drug loading capacity of different NPs are summarized in
Table 5. Vancomycin was initially loaded in PLGA NPs (PV). Due to the hydrophilic nature of
vancomycin, PV showed a limited drug loading capacity (3.8 wt%). When ZWC was added
(PZV), the drug loading was further decreased to 2.4 wt%. In general, NPs containing ZWC
were porous in SEM, most likely due to the heterogeneity of the primary emulsion (Fig. 17). The
pores might have served as water channels that allowed drug loss during purification. Particles
including additional PEG-PLGA (PpZV) showed higher loading (3.2 wt%) than PZV, but the
low yield (26.2%) suggests that the increase in drug loading was due to partial loss of PEGPLGA. Interestingly, the inclusion of E100 at 4.6-4.8 wt% of the total NP content doubled the
drug loading (8.0, 6.8 and 8.3 wt%) compared to the non-E100 counterparts (Fig. 18a) with no
reduction in the yield.
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Figure 17. SEM images of PV (left) and PZV (right) NP. Scare bar = 4 µm.

Table 5. Vancomycin encapsulation in NPs with different polymer compositions.
PLGA
(mg)

PEGPLGA
(mg)

ZWC
(mg)

E100
(mg)

Vanco
mycin
(mg)

Theor
etical
E100
conten
t (%)

Yield (%)*

Drug
loading
(%)*,†

PV

20

-

-

-

2

0

58.1 ± 9.4

3.8 ± 0.8

PZV

20

-

8

-

3

0

35.7 ± 3.1

2.4 ± 0.5

PpZV

10

10

8

-

3

0

26.2 ± 6.5

3.2 ± 0.8

PEV

18

-

-

1

2

4.8

52.2 ± 5.7

8.0 ± 0.4

PpEV

9

9

-

1

2

4.8

42.2 ± 7.4

9.5 ± 0.5

PZEV

20

-

8

1.5

3

4.6

42.7 ± 2.5

6.8 ± 1.2

PpZEV

10

10

8

1.5

3

4.6

42.5 ± 4.0

8.3 ± 0.8

*: n=3 independently and identically prepared batches
† Drug loading: mass of encapsulated vancomycin / mass of NPs

76

Figure 18. (a) Vancomycin loading (%) in NPs with and without E100. n = 3 identically and
independently prepared batches. ****: p < 0.0001 by Sidak’s multiple comparisons test. (b) The
effects of high salinity and concentrated urea on the vancomycin release from the EV NPs. n=3
identically and independently prepared batches. **: p < 0.01 by Dunnett’s multiple comparisons
test vs. DI.

3.3.2 Vancomycin has affinity for Eudragit E100 based on hydrogen bonding.
The significant increase of drug loading may be attributable to the hydrogen bonding
between vancomycin and Eudragit E100. Vancomycin is a glycopeptide antibiotic with abundant
hydrogen bond donors and acceptors, which enable high affinity binding to cell wall precursor
peptides (D-Ala-D-Ala) thereby preventing peptidoglycan crosslinking [32]. Vancomycin may
form a complex with E100 in a similar manner due to the large number of ester groups in the
polymer (Fig. 16). In other words, vancomycin may be encapsulated in NPs as a complex with
E100 rather than a small molecule (free vancomycin) and, thus, better retained in the NPs during
the washing steps. To validate this, we prepared NP complexes composed of E100 and
vancomycin (EV) by the double emulsion solvent evaporation method. The zeta potential was
+15.3 ± 0.2 mV at pH 7.4 and +15.2 ± 1.5 mV at pH 5, reflecting the positive charge of E100 in
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the EV complex. EV NPs were incubated in 1.54 M NaCl solution and 5M urea solution, which
would interfere with electrostatic [33] and hydrogen bonding interactions [34], respectively. The
increased salinity did not increase the vancomycin release, whereas 5 M urea increased the
vancomycin release from 16.8 % to 81.6 % (Fig. 18b). This result confirms that the affinity of
vancomycin for Eudragit E100 is due to the hydrogen bonding interaction between vancomycin
and E100.
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Figure 19. (a) Vancomycin release from various NPs in buffered saline with pH 7.4 and pH 5 in
1 h. **: p < 0.01 by two-tailed t-test (b) SEM images of NPs after incubation at different pH for
4 h. Scale bar= 4 μm. (c) Percentage of pore area on each NP surface in SEM images (n = 10-15
randomly selected NPs, analyzed with Fiji software). Surface pores were defined as illustrated in
Fig. 21. *: p < 0.05; ***: p < 0.001 by two-tailed t-test.
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Figure 20. Vancomycin release from PV, PZV and PpZV NP.

Figure 21. Illustration of % pore area quantification. Pore area: area under yellow dotted line.
Particle area: area under white dotted line. Percentage of pore area = Sum of pore area per
particle/particle area × 100%. Area of interest was calculated by Fiji image analysis software.
3.3.3 PpZEV NPs showed pH-sensitive release of vancomycin.
Vancomycin release from NPs was tested at pH 7.4 and pH 5 buffer, representing
extracellular and intracellular pH, respectively. The drug release reflected the role of each

80
component in the NPs. Consistent with the poor drug loading, PV, PZV and PpZV NPs released
most vancomycin in 1 h, irrespective of the pH of the medium (Fig. 20). On the other hand, PEV
showed much lower vancomycin release at both pHs, confirming the role of E100 as a retainer of
vancomycin in the NP matrix (Fig. 19a). When a half of the PLGA was replaced with PEGPLGA (PpEV), the drug release at both pHs was slightly increased due to the increased
hydrophilicity of the matrix. PZEV (PEV containing ZWC) showed greater drug release than
PpEV. This can be explained by the porous structure due to ZWC, which allowed water to better
penetrate into the NP matrix (Fig. 19b). PZEV was expected to show greater vancomycin release
at pH 5, as protonated ZWC repels the cationic EV complex; however, the difference between
pH 5 and pH 7.4 was insignificant. On the other hand, when both PEG-PLGA and ZWC were
included (PpZEV), there was a significant difference in vancomycin release between the two
pHs.
SEM images of NPs incubated at pH 5 and 7.4 provided more insight into the differential
vancomycin release (Fig. 19b). The images demonstrated differential porosities according to the
type of NPs and the pH of the incubation medium. We quantified the porosities by calculating
the pore area per NP area for each type of NPs, assuming that surface pores represent the
porosity of the NPs. Although the two-dimensional analysis has limitations in projecting
differences in three-dimensional porosities, the image analysis helped demonstrate difference
between the NPs. A notable difference due to ZWC was the pronounced porous structure. As
mentioned earlier, we speculate that the ZWC solution may have formed a crude emulsion
during the primary emulsification due to the high viscosity. Water in ZWC phase evaporated and
left the porous image on SEM. In the hydrated NPs, the pores would have been filled with ZWC
sol and served as water channels that facilitated vancomycin release. The difference due to PEG-
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PLGA was more subtle. In the absence of PEG-PLGA, both PEV and PZEV showed reduced
porosity after incubation in pH 5 (Fig. 19c). NPs containing PEG-PLGA (PpEV and PpZEV)
seemed to maintain the pores at pH 5. We speculate that PLGA matrix may have collapsed at pH
5 due to the acid-catalyzed degradation, inhibiting further drug release at pH 5. Due to the
hydrophilicity and the smaller number of acid-labile ester bonds per molecule, PEG-PLGA
helped PLGA to resist the acid-catalyzed degradation/collapse. Therefore, in PpZEV, PEGPLGA further allowed the protonated ZWC to repel the cationic EV complex from the NP
matrix.
In summary, PpZEV achieves pH-sensitive release by the interplay of PEG-PLGA (p),
ZWC (Z), E100 (E) and vancomycin (V). E100 serves as a retainer of vancomycin, forming a
non-covalent polymeric ‘prodrug’ of vancomycin (EV) with a cationic charge. ZWC functions as
a pH-sensitive release trigger based on its interaction with the cationic EV. PEG-PLGA helps
transport EV at pH 5 by resisting acid-catalyzed collapse of the polymer matrix. Once released
from PpZEV, EV continues to dissociate as E100 dissolves at acidic pH. The pH-dependent drug
release from PpZEV is summarized in a schematic diagram (Fig. 22).
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Figure 22. Schematic diagram of pH-sensitive release of vancomycin from PpZEV NPs at
different pHs.
On the basis of these observations, we chose to use PpZEV for the rest of this study. The
z-average of fresh PpZEV was 837 ± 103 nm. The zeta potential of PpZEV particles was -9.45 ±
0.40 mV at pH 7.4 and +22 ± 0.70 mV at pH 5, reflecting the presence of ZWC. The ZWC
content in PpZEV was 15.3 ± 2.1 wt% according to the ninhydrin assay.
3.3.4 PpZEV NPs were taken up by macrophages in 3 h and released vancomycin
intracellularly.
The uptake of PpZEV* (PpZEV containing BODIPY-vancomycin) by J774A.1
macrophages were observed with time-lapse microscopy over 3 h. Fluorescence signals started to
appear in the macrophages in 1 h and continued to increase in the next 2 h (Fig. 23). Almost
every macrophage had fluorescence signals in the cytosol after 3 h incubation with the NPs.
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Figure 23. Time-lapse microscopy of cellular uptake of PpZEV* NPs. Macrophages were
incubated with 50 µg/mL PpZEV* for 15 min, 30 min, 1h or 3h. Scale bar = 50 µm.
In order to keep track of the carrier (polymer) and the payload (vancomycin) separately,
confocal microscopy was performed with P*pZEV (PpZEV containing RhoB-PLGA) and
PpZEV* (PpZEV encapsulating BODIPY-vancomycin) in parallel. The intensity of both
fluorescence dyes was not influenced by the pH (Fig. 24). Since BODIPY-vancomycin replaced
only 2.5% of total vancomycin, we assumed that its influence on intracellular vancomycin
release would be minimal. BODIPY-vancomycin may not have identical physicochemical
properties as unlabeled vancomycin due to the conjugated dye; thus, its ability to represent the
unlabeled vancomycin may be limited. Nevertheless, BODIPY-vancomycin is the closest to
vancomycin among commercially available fluorescent compounds; therefore, despite the
limitation, we assumed that its fluorescence would represent intracellular diffusion of unlabeled
vancomycin. In both cases, punctate fluorescence signals appeared in the macrophages in 3 h
(Fig.25b, e, f). In contrast, no fluorescence was detected in macrophages incubated with free
BODIPY-vancomycin (Fig. 25d, h). This indicates that PpZEV NPs facilitated cellular uptake of
vancomycin via phagocytosis. It is noteworthy that vancomycin signals in the NP-treated
macrophages were slightly more diffuse than those of polymer. The vancomycin signals diffused
further into the cytosol with additional 21 h incubation (Fig. 25c, g). This indicates that
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vancomycin was partially released from the PpZEV NPs intracellularly and entered the cytosol
in 24 h.

Figure 24. Fluorescence intensity of Rhodamine B and BODIPY-vancomycin solution at
different pHs. Rhodamine B (0.45 μg/ml) and BODIPY-vancomycin (0.72 μg/ml) solutions were
prepared in PBS (pH 7.4) or acetate buffered saline (pH 5). The fluorescence intensity was
detected at λex/λem = =540 nm/620 nm for Rhodamine B and λex/λem =480 nm/520 nm for
BODIPY-vancomycin using a Synergy 4 microplate reader (BioTek, Winoosk, VT). No
statistical difference between pHs for both dyes,
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Figure 25. Confocal microscopy observation of NP uptake and vancomycin release in J774a.1
macrophages. (a, e) Macrophages incubated with 50 µg/mL Rhodamine-labeled P*pZEV NPs
(red) for 3 h. (b. f) Macrophages incubated with 50 µg/mL PpZEV* NPs (green) encapsulating
BODIPY-vancomycin for 3 h. (c, g) After additional 21 h incubation in fresh medium after 3 h
incubation with PpZEV* NPs. (d. h) Macrophages incubated with free BODIPY-vancomycin.
Blue: Nuclei stain.
3.3.5 PpZEV NPs were taken up by MRSA-infected macrophages and delivered vancomycin
to intracellular MRSA.
PpZEV NP uptake and intracellular vancomycin release were observed in MRSAinfected macrophages using dual-labeled P*pZEV* NPs. With 3 h exposure to the NPs, the
cytosols were full of punctate yellow signals indicating colocalization of polymer and
vancomycin (Fig. 27). According to image analysis, there was no significant difference in the
extent of NP uptake (judged from the BODIPY-vancomycin signal) from the non-infected
macrophages (Fig. 26). A few punctate red signals from drug-depleted NPs and slightly diffuse
green fluorescence indicating released vancomycin were also seen at this time. This suggests that
PpZEV NPs were taken up by the MRSA-infected macrophages and partially released
vancomycin, consistent with the observation in the non-infected macrophages. After additional
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21 h incubation in NP-free medium, greater green fluorescence was detected in the cytosol. In a
close-up image, green signals were seen in proximity to small blue signals of intracellular
MRSA. The circular pattern of green fluorescence, contrasted with the homogeneous
fluorescence signal seen in infection-free macrophages (Fig. 28), suggests vancomycin binding
to the spherical bacteria, comparable to vancomycin binding to free MRSA (Fig. 29).
Vancomycin signals were barely seen in the macrophages incubated with free BODIPYvancomycin. This confirms that PpZEV NPs facilitate cellular uptake of vancomycin and its
delivery to intracellular bacteria.

Figure 26. Fluorescence intensity of BODIPY-vancomycin inside uninfected and MRSAinfected cells after PpZEV* treatment for 3 h. The fluorescence intensity was quantified by Fiji
Software from the confocal images taken at the same setting (> 100 cells were analyzed for each
group).
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Figure 27. Uptake of BODIPY-vancomycin and dual-labeled P*pZEV* NPs by MRSA-infected
macrophages. MRSA-infected macrophages were incubated with BODIPY-vancomycin or
P*pZEV* NPs for 3 h, or 3 h plus additional 21 h in NP-free medium (3h + 21h). Scale bar = 50
µm. The rectangular areas were magnified to show the intracellular fluorescence distribution
(scale bar = 10 µm). Green: vancomycin; red: PLGA; blue: nuclei. The fluorescence intensity of
BODIPY-vancomycin (vancomycin*) in macrophages was quantified by the Fiji software. Free
vancomycin and PpZEV (total): Green signal of vancomycin*; PpZEV (released): Green signal
of vancomycin* - yellow signal (PLGA* + vancomycin*) = released vancomycin*. Here, yellow
signal is largely unchanged due to the saturation; thus, the increase thus, the increase in PpZEV
(total) signal over time is attributed to the increased signal of released vancomycin. **: p < 0.01;
****: p < 0.0001 by Sidak’s multiple comparisons test.
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Figure 28. Comparison of confocal images of non-infected macrophages (from Supporting Fig. 6g)
and infected macrophages (from Fig. 4) after 3 h treatment with PpZEV (containing BODIPYvancomycin) followed by additional 21 h incubation in NP-free medium.

Figure 29. Interaction of BODIPY-vancomycin with USA300 MRSA. Free MRSA was imaged after
3 h incubation with green BODIPY-vancomycin in two magnifications. Blue: MRSA; green:
BODIPY-vancomycin.
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3.3.6 PpZEV achieved >10 times higher vancomycin concentration in macrophages than free
vancomycin.
We attempted to quantify vancomycin delivered to J774A.1 macrophages via PpZEV or
free vancomycin. Macrophages were treated with PpZEV NPs or free vancomycin (both
equivalent to 4.35 µg/mL vancomycin) for 24 h. 5.57 µg of vancomycin was recovered from
2.45  107 macrophages, much greater than the quantity recovered from free vancomycin-treated
macrophages (0.408 μg recovered from 1.93  107 cells), consistent with the confocal images.
These values translate to 575.5 µg/mL and 53.5 µg/mL, respectively, given that the volume of a
single macrophage is 3.95  10-10 mL [1]. Both concentrations would be substantially higher than
the reported MIC values of vancomycin against MRSA (0.5-2 μg/mL) [2]. However, these
values do not represent exclusively intracellular vancomycin. It is rather likely to include those
bound to the macrophage surface, which could not be completely removed by washing due to the
high affinity of vancomycin for cell surface proteins.

Figure 30. Cytotoxicity of PpZEV NPs on J774A.1 macrophages. No statistical difference from the
control groups (macrophages with no treatment) by Dunnett's multiple comparisons test.
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3.3.7 PpZEV NPs enhanced reduction of intracellular MRSA.
Prior to intracellular microbial activity testing, toxicity of PpZEV NPs to J774A.1
macrophages was evaluated by the MTS assay. The viability of the macrophages was not
affected after 24 h incubation with 56 µg/mL and 112 µg/mL of PpZEV NPs, equivalent to 5 and
10 µg/mL vancomycin, respectively (Fig. 30). This indicates that PpZEV NPs would not affect
the viability of macrophages at the concentrations used for evaluation of intracellular
antimicrobial activity.
Antimicrobial activity of different NPs against intracellular bacteria was evaluated in
J774A.1 macrophages infected with MRSA USA400, a community acquired MRSA strain
predominant in the United States [3]. The MRSA-infected macrophages were incubated with
NPs or free vancomycin at an equivalent vancomycin dose (5 µg/mL) for 24 h. Of note, since the
tested NPs had different drug loading capacities (Table 5), the amounts of NPs corresponding to
the specific dose of vancomycin were unequal. We assumed that this variation would have
minimal influence on macrophage uptake of the NPs given the phagocytic nature of
macrophages. After 24 h incubation with the vancomycin treatment, the cells were washed and
lysed, and the colony forming units (CFU) of MRSA in the cell lysate were compared. PpZEV
NPs that had shown high drug release (Fig. 19a) showed the greatest anti-bacterial activities
against intracellular MRSA (Fig. 5a), whereas PEV NPs with the least drug release was virtually
ineffective. It is worthwhile to note that PV, PZV and PpZV did not show significant reduction
in intracellular MRSA despite the high drug release (Fig. 20, Fig. 31a). The main difference
between PpZEV and these NPs is that the former released less vancomycin in pH 7.4 than the
latter. This indicates that intracellular antibacterial activity was driven by the vancomycin
released in the cells (i.e., at acidic organelles) rather than the drug released prior to macrophage
uptake.
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Figure 31. (a) Log-fold reduction of intracellular MRSA USA 400 by different NPs and free
vancomycin. *: p < 0.05; **: p < 0.01; ***: p < 0.001; and ****: p < 0.0001 by Tukey's multiple
comparisons test. (b) Difference in vancomycin release between pH 7.4 and pH 5 in 1h. *: p <
0.05 by Tukey's multiple comparisons test. (c) Correlation of drug release difference at two pHs
and intracellular antibacterial effects. All treatments were equivalent to 5 µg/mL vancomycin.
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Peterson’s correlation analysis shows a positive relationship (r = 0.8313, p = 0.0205)
between the intracellular antibacterial activity (Fig. 31a) and the difference in drug releases at
two pHs (Figs. 31b&c), indicating that the intracellular drug release was critical to the
antibacterial activity in MRSA-infected macrophages.
3.3.8 PpZEV NPs showed superior antibacterial activities against different intracellular
pathogens resident in J774A.1 macrophages.
The antibacterial activities of PpZEV NPs were tested against an extended collection of
intracellular bacteria and compared with those of free vancomycin at an equivalent dose. PpZEV
(equivalent to 5 µg/mL vancomycin) showed superior antibacterial activities to those of free
vancomycin against most intracellular bacteria (Fig. 32a). In particular, PpZEV exhibited 100
times greater antibacterial effect against intracellular Listeria than free vancomycin. When the
dose was doubled (equivalent to 10 µg/mL vancomycin), the difference between PpZEV and free
vancomycin was more pronounced in several strains, such as MRSA USA1000, 1100 and S.
pneumoniae 51916 (Fig. 32b). Blank carrier (PpZE) did not possess any antibacterial effect on
free bacteria or intracellular bacteria (data not shown); therefore, the superior effect of PpZEV is
attributable to intracellular delivery of vancomycin.
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Figure 32. Intracellular antimicrobial activity of PpZEV against important Gram-positive
bacterial pathogens. (a) PpZEV: 56 µg/mL (equivalent to 5 µg/mL vancomycin); *: p < 0.01;
***: p < 0.0001 by Sidak's multiple comparisons test, (b) PpZEV: 112 µg/mL (equivalent to 10
µg/mL vancomycin); *: p < 0.01; **: p < 0.001; ***: p < 0.0001 by Sidak's multiple
comparisons test.
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Figure 33. Uptake of dual-labeled P*pZEV* NPs and BODIPY-vancomycin by healthy (noninfected) macrophages. J774A.1 macrophages were incubated with (a) P*pZEV* NPs or (b) free
BODIPY-vancomycin for 3 h or 24 h. (c) Fluorescence intensity of BODIPY-vancomycin
(vancomycin*) inside cells quantified by Fiji Software.
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3.3.9 Intracellular release kinetics of vancomycin may explain incomplete elimination of
intracellular MRSA.
PpZEV showed greater activities against intracellular bacteria than free vancomycin, but
it did not completely eliminate them. It was difficult to determine the concentration of
exclusively intracellular vancomycin, as described in Section 3.3.6. Nevertheless, if we consider
efficient cellular uptake of NPs evident from the confocal microscopy, we may speculate that the
amount of PpZEV delivered into the cells was sufficiently high but intracellular vancomycin
release has been suboptimal. Specifically, we noted that macrophages incubated with duallabeled P*pZEV* for 3 h and 24 h showed persistent yellow signals (Fig. 27&33) indicating the
colocalization of RhoB-PLGA and BODIPY-vancomycin. This suggests that vancomycin release
in the acidic organelles was incomplete, in contrast to the prediction based on in vitro drug
release at pH 5 (Fig. 19). We were curious to know if intracellular vancomycin release was more
restricted than in release medium due to the limited escape of NPs and the released vancomycin
from the phagosomes. To validate this, macrophages were incubated with the dual-labeled
P*pZEV* NPs for 3 h or with additional 24 h in NP-free medium and lysed with Triton X100.
The phagocytosed NPs were separated from the cell lysate and imaged with confocal
microscopy. In parallel, P*pZEV* NPs incubated in buffers (pH 7.4 and pH 5) were also imaged
along with fresh NPs. Fresh NPs with no drug release showed bright yellow signals indicating
complete overlap of vancomycin (green) and polymer (red) signals (Fig. 34a). The NPs
incubated in pH 5 buffer for 1 h showed red polymer signals due to the depletion of vancomycin
(Fig. 34c), and those in pH 7.4 buffer intermediate signals indicating partial drug release (Fig.
34b), consistent with the in vitro drug release. On the other hand, the NPs incubated in the
macrophages for 3 h or additional 24 h showed all three colors, confirming incomplete
intracellular drug release (Figs. 34d and 34e). The incomplete drug release may be caused by the
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lack of phagosomal escape of PpZEV NPs after phagocytosis, which will result in drug
saturation in the organelles and thus hamper further vancomycin release from the NPs.
In this regard, we note that the current practice of in vitro release kinetics carried out in a
large volume of medium does not necessarily reflect this challenge and may lead to an
overestimation of the intracellular drug activities. For promoting the phagosomal escape,
strategies used in gene delivery may be considered, including the use of fusogenic lipids [4] and
cell penetrating peptides (CPPs) [5] with the endosomolytic activity, such as dfTAT and GALA
peptides [6, 7]. Since these peptides can disrupt the phagosomal membranes, vancomycin
confined in the phagosome will be released to the cytosol and help release the remaining
vancomycin from the NPs by providing an unsaturated environment [6, 8].

Figure 34. Confocal images of dual-labeled P*pZEV* NP at different conditions: (a) Fresh NPs,
(b) NPs incubated in pH 7.4 buffered saline for 1 h, (c) NPs incubated in pH 5 buffered saline for
1 h, (d) NPs recovered from cells after 3 h incubation, and (e) NPs recovered from cells after 3 h
incubation and additional 24 h incubation in fresh medium. Scale bars = 50 µm. (f) Semiquantitative assessment of the extent of drug release based on image analysis by Fiji software,
based on 2-3 images per condition.
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3.3.10 PpZEV NPs accumulated in the liver and spleen in 10 min.
We next turned our attention to evaluate the tissue distribution of NPs in vivo. BALB/c
mice were injected with PpZEV NPs via tail vein and imaged over time. For whole body
fluorescence imaging, PpZEV NPs were loaded with DiR near infrared fluorescent dye. DiR is
well retained in the particles suspended in 50% serum, and free DiR is not intensely fluorescent
in aqueous medium due to aggregation and also rapidly eliminated via the RES organs and the
kidneys [9]. Therefore, DiR encapsulated in PpZEV is suitable for representing the NPs in vivo.
As shown in Fig. 35, strong DiR signal was observed in the liver and spleen in 10 min. Those
organs showed persistent signals till 3 h post-injection and gradually decreased over the next 93
h. Ex vivo images of organs at 3 h and 96 h post-injection confirmed the preferential
accumulation of NPs in the liver and the spleen and very little in other organs including blood.
Rapid accumulation of NPs in these organs is desirable for two reasons: First, the liver and the
spleen are the target organs where infected macrophages are predominantly located. Second, NPs
spend little time in circulation prior to the tissue distribution; thus, the premature drug release is
less concerning than in other applications requiring long-term circulation. At present, we do not
know whether the decreasing fluorescence signal over time indicates the elimination of NPs from
the organs or slow release of DiR from the NPs. It also remains to be seen how rapidly the
resident macrophages will take up the accumulating NPs, although in vitro observation suggests
that this process be quick (Fig. 23).

98

Figure 35. (a) Whole body imaging of BALB/c mouse that received DiR-loaded PpZEV NPs by
intravenous injection. V: ventral view; D: dorsal view. See Supporting Fig. 13 for all 3 animals.
(b) Ex vivo imaging and fluorescence intensity of major organs at 3 h or 96 h post-injection.
From the top: heart (H), lung (Lu), liver (L), spleen (S), kidneys (K), gastrointestinal tract (GI),
and blood (B) (n = 3 per time point).

3.4

Conclusions
We developed vancomycin-loaded pH-sensitive PpZEV NPs with polymers providing

distinct functions: PLGA as the main delivery platform, PEG-PLGA to facilitate drug release,
Eudragit E100 to enhance vancomycin loading, and ZWC to trigger lysosomal vancomycin
release. PpZEV NPs were superior to free vancomycin in killing intracellular MRSA and other
intracellular pathogens due to their ability to facilitate the cellular uptake of vancomycin and its
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delivery to the intracellular bacteria. In mice, intravenously administered PpZEV NPs rapidly
accumulated in the liver and spleen, the target organs of intracellular infection.

3.5
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EVALUATION OF OPTIMIZED PPZEV
NANOPARTICLES IN METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS-INFECTED MOUSE MODEL

4.1

Introduction
In Chapter 3, we described vancomycin-loaded pH-sensitive PpZEV NPs that can

efficiently encapsulate and deliver vancomycin to the intracellular pathogens. Eudragit E100 was
included in the PLGA matrix to increase drug loading via hydrogen bonding, and ZWC was
added to trigger drug release at acidic pH through electrostatic repulsion between ZWC and
E100/vancomycin complex. Due to the size (500-1000 nm) and interplay between the
components, particles were readily taken up by the macrophages, released vancomycin in the
acidic endo/lysozymes, and effectively killed intracellular pathogens in vitro, leading to
enhanced intracellular antimicrobial effects than free vancomycin. However, the burst drug
release at physiological pH remains a challenge for in vivo application because it means
premature drug loss before arrival at the target.
In this study, we aim to optimize PpZEV NPs with enhanced circulation stability without
affecting drug release at lysosomal pH. The optimization was achieved by titrating ZWC and
vancomycin feeds in the PpZEV NPs. The activity against intracellular bacteria of the optimized
PpZEV NPs was evaluated in a MRSA-infected mouse model. To investigate the delivery of
PpZEV on a cellular level, the liver and spleen were analyzed by flow cytometry and confocal
microscopy.
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4.2

Materials and Methods

4.2.1 Materials
Vancomycin hydrochloride, ninhydrin, hydrindantin, fetal bovine serum (FBS) and
Mueller-Hinton broth (MHB) were purchased from Sigma-Aldrich (St. Louis, MO). PLGA
(50:50 LA:GA, 0.15-0.25 dL/g, acid-terminated) was purchased from LACTEL® (Denver, CO).
mPEG -PLGA (mPEG- 5kDa, PLGA 50:50 LA:GA 4 kDa) and RhoB-PLGA (LA:GA 50:50,
ester-terminated, 30 kDa) were purchased from Akina, Inc. (West Lafayette, IN). Eudragit E100
was a gift from Evonik (Darmstadt, Germany). Dichloromethane (DCM), and acetonitrile (ACN)
were obtained from Fisher Scientific (Hampton, NH). Hoechst 33342, and Dulbecco's Modified
Eagle's medium (DMEM) were purchased from Life Technology (Carlsbad, CA). Zwitterionic
chitosan (ZWC) was synthesized according to the previously reported method. Deionized (DI)
water was obtained from a Milli-Q ultrafiltration system (Millipore, Billerica, MA). Type 4
Collagenase was purchased from Worthington (Lakewood, NJ). ACK lysing buffer and Alexa
Fluor 488 labeled F4/80 Monoclonal Antibody were purchased from Thermo Fisher Scientific
(Waltham. MA). Cell staining buffer was obtained from BioLegend (San Diego, CA).
4.2.2 Nanoparticle preparation
The optimized PpZEV NPs (Opt-PpZEV, Z2V15in Table 6) were prepared by water-oilwater double emulsion according to the previously reported method with minor modifications.
The organic phase containing 10 mg PLGA, 10 mg PEG-PLGA and 1.5 mg Eudragit E100 was
created by dissolving into 4 mL dichloromethane (DCM). Fifteen milligrams of vancomycin
were solubilized in 300 μl DI water supplemented with 90 μl 0.1N NaOH and emulsified into the
organic phase using a SONICS® Vibra-Cell ultrasonic liquid processor (Newtown, CT) at 25%
power pulsed (1s on, 1s off) for 1 min, followed by adding 400 μL aqueous solution containing 2
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mg ZWC0.3 with 3 min additional sonication. The primary emulsion was then transferred to 20
mL 1% polyvinyl alcohol (PVA) solution and homogenized using Silverson® homogenizer (East
Longmeadow, MA) at 5,000 rpm for 3 min to form a W1/O/W2 double emulsion. The resultant
was poured into 40 mL DI water and stirred 20 min at room temperature. The residual DCM was
completely removed by rotary evaporation for 30 min. The NPs were collected by centrifugation
at 8,891 rcf for 10 min, washed with water twice, and lyophilized by a Labconco freeze-dryer
(Kansas City, MO). 0.1N NaOH was supplemented to all the aqueous phase for maintaining
neutral pH during the NP preparation. For comparison, NPs with varying amounts of ZWC or
vancomycin (Table 6) were prepared in the same way without changing the feed of other
components. For flow cytometry and confocal microscopy, rhodamine B-labeled opt-PpZEV
NPs were prepared in the same way except for the replacement of 20% of PLGA with RhoBPLGA.
4.2.3 Particle characterization
Particle size and zeta potential were measured by Malvern Zetasizer Nano ZS90
(Worcestershire, UK). The size NPs were measured in 5mM pH 7.4 phosphate buffer. The zeta
potential was determined in 5 mM pH 7.4 or 5 mM pH 5.0 acetate buffer. Particle morphology
was observed by a FEI Nova NanoSEM scanning electron microscopy and a FEI Tecnai T20
transmission electron microscopy. For TEM measurement, freeze-dried NPs dispersed in water
as 0.1-0.3 mg/mL was spotted on formvar-coated carbon grid (400 mesh) and directly examined.
To determine vancomycin loading in the NPs, 2 mg of lyophilized NPs were dissolved in
1 mL DMSO. After precipitating PLGA polymer with the addition of 1 mL DI water, the sample
was centrifuged at 12,126 rcf for 20 min, and the supernatant was analyzed by the HPLC. The
drug loading (%) was calculated as the amount of vancomycin divided by the mass of NPs.
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4.2.4 In vitro release of vancomycin from NPs
Vancomycin release from NPs was tested with centrifugation method. NPs were
dispersed in PBS (pH 7.4) or acetate buffered saline (pH 5.0) and incubated at 37 °C with
continuous shaking. After one hour, the suspension was centrifuged at 12,126 rcf for 20 min, and
the released vancomycin in the supernatant was analyzed by HPLC. The pellets were rinsed once
with small volume of DI water, lyophilized and imaged with SEM.
4.2.5 In vitro macrophage uptake
The cellular uptake of opt-PpZEV NPs were observed with J774a.1 and Raw 264.7
macrophages. Both cells were grown in DMEM medium supplemented with 10% FBS, 100
units/mL penicillin, and 100 μg/mL streptomycin. The macrophages were seeded in 6-well plate
at a density of 200,000 cells/well and incubated overnight at 37°C. The medium was removed
and replaced with 50 µg/mL RhoB-labeled opt-PpZEV NPs or fresh medium in the presence of
10% FBS. After 24 h, the medium was removed and washed twice with fresh medium. The cells
were detached from the plate by cell scraper and analyzed by an Accuri C6 flow cytometer (BD
Biosciences, San Jose, CA).
4.2.6 Macrophage uptake in liver and spleen
12-week old C57BL/6 were obtained from Envigo (Indianapolis, IN). Each animal
received 1.5 mg RhoB-labeled opt-PpZEV NPs via tail-vein injection. After 24 h, the animals
were deeply anesthetized by isoflurane inhalation, and the heart was perfused with 20 mL PBS to
remove red blood cells from the system. The liver and spleen were excised, minced and
dispersed in 5 mL PBS containing 0.1% Type IV Collagenase, 0.01% Hyaluronidase and 30
units/mL DNase 1 at room temperature with gentle agitation for 30 min. Following digestion, the
tissue homogenate was mixed with 45 mL DMEM medium (10% FBS included) and filtered
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through 100 μm cell strainer to remove the undigested tissue. The cell suspension was
centrifuged at 300 rcf for 5 min to remove the supernatant. The cell pellets at the bottom were resuspended in 5 mL ACK cell lysis buffer for removing the remaining red blood cells. After
collecting cells by centrifugation at 300 rcf for 5 min, the cell sediments were re-dispersed in 10
mL DMEM medium and filtered by 70 μm cell strainer again. The cell population was counted
by hemocytometer. A million cells dispersed in 100 μL cell staining buffer were incubated with
0.4 μg of Alexa 488 F4/80 monoclonal antibody at 4°C for 1 h. The cells were washed twice
with 1 mL ice-cold PBS and analyzed by Accuri C6 flow cytometer. Prior to confocal
microscopy, the cells were fixed by 1% Paraformaldehyde (PFA) and the nuclei were stained
with Hoechst 33342. The cells were mounted on a cover slip with Clearmount (Zymed, San
Francisco, CA), and imaged with confocal microscopy.
4.2.7 Maximum tolerated dose (MTD) determination
All animal procedures were approved by Purdue Animal Care and Use Committee, in
conformity with the NIH guidelines for the care and use of laboratory animals. The MTD was
determined according to the method suggested by the National Cancer Institute's Developmental
Therapeutics Program [1]. Three healthy 8-week old male C57BL/6 mice were obtained from
Envigo (Indianapolis, IN), and each mouse opt-PpZEV NPs suspended in the sterile PBS at
different doses (150, 300 and 450 mg/mL NPs, corresponding to 51, 102 and 153 mg/kg
vancomycin) via tail-vein injection. The body weight of each mouse was monitored for 2 weeks
post-injection, and MTD was determined as the highest dose tolerated without > 20% body
weight loss or other signs of significant toxicity.
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4.2.8 Antimicrobial activity of PpZEV NPs in MRSA-infected mouse model (With the
courtesy of Dr. Haroon Mohammad at Seleem lab)
6-8 weeks old female BALB/c mice were obtained from the Jackson Laboratory (Bar
Harbor, ME). The murine model of systemic MRSA infection was established by intraperitoneal
injection (200 µL) of 3.7 × 108 CFU/mL MRSA USA300. One-hour post-infection, the animals
were randomly assigned to 5 treatment groups (n=5 per group). The first group (i) received PBS
(negative control), and three groups (ii, iii, iv) received one dose of vancomycin, PpZEV NP or
opt-PpZEV NP equivalent of 25 mg/kg vancomycin through tail-vein injection. The fifth group
of mice (v) were given one dose of opt-PpZEV (25 mg/kg vancomycin) and the second dose of
opt-PpZEV (25 mg/kg vancomycin) at eight hours after the initial dose. All mice were humanely
euthanized via CO2 asphyxiation 12 hours after the administration of second dose. The liver,
spleen, and lung were harvested aseptically. The tissues were weighed and homogenized in PBS
using an Omni Tissue Homogenizer (Omni International, Kennesaw, GA). To determine the
bacterial load in the tissues, the homogenate was serially diluted in PBS and aliquots (4 μL) of
each dilution were plated on mannitol salt agar plates. The plates were incubated at 37°C for 20
h, and the colony forming units (CFU) were counted.
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Table 6. Vancomycin encapsulation in PpZEV NPs prepared with different amounts of ZWC and
vancomycin.
PLGA

PEG-

ZWC

E100

Vancomycin

Theoretical

Drug

(mg)

PLGA

(mg)

(mg)

(mg)

E100 content

loading

(%)

(%)

(mg)
Z8V3

10

10

8

1.5

3

4.6

8.3 ± 0.8

Z4V9

10

10

4

1.5

9

4.3

21.5

Z2V9

10

10

2

1.5

9

4.6

28.2

Z2V12

10

10

2

1.5

12

4.2

32.8

Z2V15

10

10

2

1.5

15

3.9

37.0 ± 2.1

Z2V18

10

10

2

1.5

18

3.6

32.1

4.3

Results and Discussion

4.3.1 Optimization of PpZEV NPs with enhanced pH-sensitivity and drug loading
Previously, we produced PpZEV NPs with 10 mg PLGA, 10 mg PEG-PLGA, 8 mg
ZWC, 1.5 mg ZWC and 3 mg. It showed superior antimicrobial activity against different
intracellular pathogens to free vancomycin in vitro. However, it released nearly 70% of
vancomycin at pH 7.4 in 1 h, which is a significant weakness in systemic application. The
previous PpZEV Z8V3 (referring to 8 mg ZWC and 3 mg vancomycin) NPs showed a porous
structure at pH 7.4, attributable to the high viscosity of ZWC phase interfering with
homogeneous mixing during the primary emulsification. The pores may have served as water
channel and facilitated burst drug release in the presence of water.
In order to reduce the pore formation, thereby preventing the premature drug release, we
decreased the amount of ZWC and observed the drug release profiles at pH 7.4 and pH 5. As
shown in Fig. 36, with the decrease of the ZWC content (8, 4 and 2 mg), the vancomycin release
at pH 7.4 diminished without reducing the drug release at pH 5. In particular, with 2 mg of ZWC
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(Z2V9), 14.4% of vancomycin was released at pH 7.4 and 83.5% at pH 5, making the drug
release difference at two pHs as high as 69% (Fig. 36a). Accordingly, we chose 2 mg ZWC for
the following studies. We also titrated the vancomycin feed (9 mg, 12 mg, 15 mg and 18 mg)
fixing the ZWC at 2 mg (Z2V9, Z2V12, Z2V15 and Z2V18), so as to maximize vancomycin
loading capacity in the PpZEV NPs (Table 6). The vancomycin loading increased with the feed,
reaching a maximum of 37.0 ± 2.1% with Z2V15 (Table 6). The increase of vancomycin feed
also increased the drug release at pH 7.4 (Fig. 36b), likely due to excessive vancomycin
deposited near the surface of NPs. We chose PpZEV Z2V15 as the optimal NPs (opt-PpZEV
NP), since it showed the highest drug loading capacity while maintaining a better stability than
the original PpZEV (Z8V3) at pH 7.4. Hereafter, opt-PpZEV NPs refers to Z2V15 and original
PpZEV does Z8V3.

Figure 36. Vancomycin release from PpZEV NPs composed of different amounts of ZWC and
vancomycin.
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Figure 37. SEM images of NPs before and after incubation at different pH for 1 h. Scale bar = 4
μm for upper images, 3 μm for lower images. Magnification: 20,000×

4.3.2 Characterization of opt-PpZEV NPs
The z-average of opt-PpZEV NPs was 1082 ± 129 nm. The zeta potential of opt-PpZEV
NP was -12.25 ± 1.63 mV at pH 7.4 and +19.95 ± 0.35 mV at pH 5, indicating the presence of
ZWC. The existence of ZWC was also reflected by the SEM images of particle morphology.
Similar to the original PpZEV NPs, opt-PpZEV NPs showed porous structure after
lyophilization, due to the heterogeneity of primary emulsion caused by ZWC. Upon incubation at
pH 7.4 and pH 5, the pores from opt-PpZEV were not as pronounced as those from original
PpZEV (Fig. 37). Previously we speculated that the big pores in original PpZEV would have
been filled with ZWC-sol and served as water channels to facilitate vancomycin release, leading
to 67.3 ± 7.7 % burst drug release at pH 7.4 in 1 h. Consistently, the opt-PpZEV released only
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38.8 ± 0.3% vancomycin at pH 7.4, probably due to the reduction of ZWC leading to reduced
water channels.
4.3.3 MTD of opt-PpZEV NPs
To determine MTD, we administered C57BL/6 mice with 450, 300 and 150 mg/kg of
opt-PpZEV (equivalent to 153, 102 and 51 mg/kg vancomycin) by tail-vein injection (Fig. 38).
The mouse receiving 450 mg/kg NPs showed apparent signs of pain (hunched posture, squinted
eyes and reluctance to move) in two days, resulting in early euthanasia. Mice receiving 300 and
150 mg/kg of NPs survived the treatments with minimal weight loss (Fig. 38). Therefore, we
determined 300 mg/kg as the MTD of opt-PpZEV NPs in mice for the following efficacy
evaluation.

Figure 38. Measurement of mouse body weight post-NPs injection.
4.3.4 PpZEV NP was superior to vancomycin in vivo
To test the efficacy of PpZEV NPs in vivo, murine model of MRSA-infection was
generated by intraperitoneal injection of MRSA USA300, the most widespread communityassociated MRSA clone on the American continent [2]. After 1 h post-bacterial infection, the
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mice received either PBS, free vancomycin, PpZEV or opt-PpZEV NPs, equivalent to 25 mg/mL
vancomycin. When evaluated 20 h after treatment, free vancomycin showed no statistically
significant antibacterial activity (Fig. 39). In contrast, the number of bacteria observed in the
livers and spleens of mice treated with PpZEV or opt-PpZEV NPs were significantly lower (p <
0.05, Tukey multiple comparison). However, only opt-PpZEV NPs showed significant difference
in antimicrobial activity compared to free vancomycin. Nevertheless, the effect of optimization
was marginal as evident from insignificant difference between original PpZEV and opt-PpZEV.
It implies that the instability in the physiological pH was not as critical as we envisioned, since
the NPs did not spend much time in the circulation before they arrived at the RES organs.

Figure 39. Antimicrobial activity of PpZEV against MRSA resident in liver and spleen (1st trial).
*: p< 0.05; **: p < 0.01 by Tukey multiple comparisons test. N = 4 or 5. With courtesy of Dr.
Haroon Mohammad.

To reconfirm in vivo efficacy, additional set of animal experiments were performed (Fig.
40). This time, 4 out of 7 mice receiving original PpZEV NPs died, and the remaining three mice
appeared very sick or lethargic. Closer inspection of the liver tissues in these mice revealed
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unusual dart spots, an indication of potential embolism. Given that NPs composed of high
Eudragit E100 content was found toxic to macrophages in vitro (Fig.15a) and opt-PpZEV NPs
showed dose dependent toxicity in vivo (Fig. 38), the potential toxicity of E100 should not be
ruled out. All the mice receiving opt-PpZEV NPs survived, and the MRSA counts in liver and
spleen were significantly lower than the ones receiving free vancomycin, consistent with the first
in vivo result. No lesions were observed in the major organs, indicating E100-derived toxicity
was not as significant as the animals receiving original PpZEV NPs. This may be explained by
high drug loading in opt-PpZEV NPs, which reduced the required NP dose (hence less E100) for
an equivalent vancomycin dose. The reduced toxicity is a clear advantage of opt-PpZEV over
original PpZEV. Additional dose of opt-PpZEV NP did not further reduce the bacteria counts in
these tissues, suggesting that the delivery of opt-PpZEV NPs might have been maxed out.

Figure 40. Antimicrobial activity of PpZEV against MRSA resident in liver and spleen (2nd trial).
**: p< 0.01; ***: p < 0.0001 by Dunnett’s multiple comparisons test. #: p < 0.05; ###: p < 0.001;
####: p < 0.0001 by two-tailed unpaired t test. N = 5
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4.3.5 Opt-PpZEV NP distribution in the liver and spleen
Previously, we used whole-body imaging technique to trace the organ distribution of
PpZEV NPs in the mouse model and identified the liver and spleen as the main organs that took
up the DiR labeled PpZEV NPs in 10 min (Fig. 35). We investigated the NP distribution in the
RES organs on a cellular level by flow cytometry.
Prior to in vivo study, the cellular uptake of RhoB-PpZEV (Rhodamine labeled optPpZEV) by macrophages were confirmed using J774a.1 and Raw 264.7 macrophages as cell
models (Fig. 41). After 24 h incubation with the NPs, 94.1% of J774a.1 and 78.7% for Raw
264.7 macrophages were NP-positive. This indicates that macrophages readily take up optPpZEV NPs, likely due to the size (500-1000 nm) optimal for macrophage uptake.

Figure 41. Cellular uptake of Rho-PpZEV in J774a.1 and Raw 264.7 cells. Both cells were
incubated with Rhodamine B labeled opt-PpZEV NPs for 24 h and analyzed by flow cytometry.
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To examine whether PpZEV was taken up by macrophages in vivo, 1.5 mg of RhoBPpZEV NP was intravenously injected to a mouse. The cells harvested from the liver and spleen
were stained with F4/80 antibody, a general surface marker for mature macrophages such as
Kupffer cells, splenic red pulp macrophages, peritoneal macrophages and Langerhans cells [3],
and analyzed by flow cytometry (Fig. 42a) as well as confocal microscopy (Fig. 42b). In the
liver, 78.4% of F4/80high cells showed NPhigh, indicating most Kupffer cells took up NPs. In
addition, among the NP-positive cells, 65.5% were Kupffer cells. The remaining 35.5% cells
may be infiltrating macrophages or dendritic cells, which express low levels of F4/80 epitope.
This result is consistent with the fact that Kupffer cells prevalent in the hepatic sinusoids allows
them to efficiently phagocytose pathogens and particulates introduced from the portal or arterial
circulation [4]. Since infiltrating macrophages and dendritic cells are also present in the sinusoid
[4], some portion of NPs in the circulation may have been taken up by these professional
phagocytes.
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Figure 42. Macrophage uptake of RhoB labeled opt-PpZEV NPs in liver. (a) Liver parenchymal
and non-parenchymal cells from NP-treated or untreated mouse were stained with F4/80
antibody and analyzed by flow cytometry. (b) Visualization of NP-containing macrophages
(yellow arrow) via confocal microscopy.

The macrophage population in spleen is more heterogeneous than in the liver. It is
composed of three types of macrophages: red pulp, white pulp, and marginal zone macrophages,
and only red pulp macrophages are F4/80 positive. With the NP administration, 70.1% of
F4/80high were NPhigh, indicating 70.1% of red pulp macrophages contained PpZEV NP (Fig. 43).
Among the cells that captured NPs, red pulp macrophages accounted for 68.2%. This agrees with
the literature report that particles larger than 100-200 nm are incapable of crossing the
endothelial slit of splenic sinuses [5] and NPs with smaller size (<200 nm) are likely to be taken
up by the marginal zone macrophages [5]. We speculate that the majority of PpZEV NPs are
retained in the red pulp and internalized by red pulp macrophages due to the large size.
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Nevertheless, the size distribution of opt-PpZEV NPs is broad, and the relatively small NPs may
have been taken up by marginal zone macrophages, which are F4/80 negative.

Figure 43. Macrophage uptake of RhoB labeled opt-PpZEV NPs in spleen. (a) Spleen cells from
NP-treated or untreated mouse were stained with F4/80 antibody and analyzed by flow
cytometry. (b) Visualization of NP-containing macrophages (yellow arrow) in spleen via
confocal microscopy.
4.4

Conclusion
PpZEV NPs were optimized with respect to vancomycin loading and stability at

physiological pH. After optimization, the burst drug release was ameliorated, and the drug
loading was increased by fourfold. High drug loading is beneficial, because it reduces not only
the potential adverse effects from the excipients but also the manufacturing cost of nanomedicine
[6]. Opt-PpZEV NPs were superior to free vancomycin in killing MRSA loads in the liver and
spleen due to its fast accumulation in those organs, specifically facilitating vancomycin delivery
to the macrophages where the intracellular bacteria predominantly resided. No toxicity was
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indicated from opt-PpZEV NPs according to body weight change and gross appearance of
tissues. In the future, the acute cytotoxicity will be evaluated by blood chemistry and histology.
Taken together, the in-vivo studies in this chapter demonstrated that a single dose of opt-PpZEV
NP performed better than free vancomycin in reducing bacteria counts in liver and spleen, due to
efficient delivery of vancomycin to the macrophages via NP carriers, which is consistent with the
in vitro intracellular antimicrobial activity shown in Chapter 3.
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DEVELOPMENT OF A NEW ENCAPSULATION
METHOD FOR INTRACELLULAR DELIVERY OF HYDROPHILIC
MOLECULES

5.1

Introduction
In the previous studies, we have encapsulated hydrophilic drug vancomycin in the PLGA

matrix with high efficiency. However, the high drug loading was only achieved by blending
Eudragit E100, which helps retain vancomycin in the PLGA matrix via hydrogen bonding
interaction. The weakness of this method is that the amount of E100 in the formulation had to be
carefully controlled due to its toxicity. Therefore, we explored alternative polymeric
nanoparticulate systems which can efficiently encapsulate hydrophilic drugs like vancomycin
without using E100.
Various nanoparticle platforms have been developed for delivering hydrophilic drugs,
such as liposomes, nanogels and polymeric nanoparticles. However, the liposomes prepared by
passive loading method generally suffer from low drug loading (drug/NP, <5%) [1-3]. Remote
loading method has been used to enhance drug entrapment, but it is effective to drugs with pKa
higher than 3.6 [4]. Also, lipid excipients in liposomes increase the production cost. Being
mostly hydrophilic in nature, nanogels have been used as carriers of hydrophilic molecules, such
as nucleic acids and proteins. It is either prepared by physical cross-linking through hydrophobic,
hydrogen bonding or electrostatic interactions, or by chemical cross-linking through free radical
crosslinking polymerization or adopting polymeric precursors [5]. By physical crosslinking, the
size of nanogel is difficult to control since non-covalent bond between polymer chains are
relatively weak [6]. Although chemical cross-linking renders more stable nanogels than the
physically cross-linked ones, it involves more complicated synthesis steps and the use of
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crosslinking agents may cause unwanted toxic effects [7]. Several researchers used inverse
emulsion polymerization technique to encapsulate hydrophilic molecules in the polymeric
nanoparticles [8]. Briefly, aqueous phase containing hydrophilic monomers and drugs was
emulsified in continuous organic phase in the presence of surfactants, followed by the addition of
a polymerization initiator to form drug-loaded polymeric nanoparticles. A primary concern for
this approach is the use of organic solvents and reactive monomers, either of which can cause
undesirable cytotoxicity if incompletely removed.
Considering these limitations, we aim to develop tannic acid nanocapsules which can
efficiently encapsulate hydrophilic drugs. Tannic acid (TA), a natural polyphenol from plants, is
an inexpensive GRAS (generally considered as safe) substance approved by the FDA as food
additives; thus, it makes an appealing material as a pharmaceutical excipient. TA has attracted
interests due to its potential to serve as a coating material for surface functionalization [9, 10].
According to Ejima et al, TA and Fe(III) ions can form films on the surface of different
substrates such as glass, metal and polymers via multivalent coordination bonding [11]. In
addition, Shen et al. encapsulated paclitaxel in nanocapsules formed by interfacial assembly of
TA-Fe(III) shells between ethanol droplets and aqueous continuous phase. This method not only
provided high drug loading (>50% paclitaxel/NP) but also enhanced colloidal stability by
suppressing the Oswald ripening of paclitaxel nanocore [12]. Inspired by Shen’s study, we
synthesized polymerized TA nanocapsules (pTA NPs) by coordination of tannic acid with Fe(III)
via quasi-emulsion method modified from the inversion emulsion technique. In the quasiemulsion method, the organic continuous phase was replaced by glycerol, making the
nanoparticle synthesis solvent-free and eco-friendly. Three hydrophilic anitibiotics, RRIKA,
vancomycin, polymycin B and one model DNA (salmon DNA) were encapsulated in the pTA
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NPs. To increase the drug loading, phosphate and/or calcium ions were added as additives in
selected NPs. The nanocapsules were produced in the range of 200-600 nm and were able to
encapsulate 10-20% RRIKA, polymyxin B and vancomycin (Drug per NP, mass ratio),
indicating the utility for intracellular drug delivery to phagocytes such as macrophages and
dendritic cells [13].

Figure 44. Structures of RRIKA, polymyxin B and vancomycin.
5.2

Materials and Methods

5.2.1 Materials
RRIKA peptide (Sequence: WLRRIKAWLRRIKA) was synthesized by Genscript
Biotech (Piscataway, NJ). Tannic acid, Fe (III) chloride, vancomycin hydrochloride, polymyxin
B and Deoxyribonucleic acid sodium salt from salmon testes were purchased from Sigma-
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Aldrich (St. Louis, MO). Pluronic® F127 was a gift from BASF (Ludwigshafen, Germany).
Ultrapure glycerol was purchased from Invitrogen (Carlsbad, CA).
5.2.2 Preparation of nanocapsules
pTA-RRIKA: One milligram of RRIKA dissolved in 50 μL 0.1N HCl was premixed with
50 μL of 0.1N NaOH and 50 mg/mL F127. The mixture was emulsified into 2 mL ultrapure
glycerol with SONICS® Vibra-Cell ultrasonic liquid processor (Newtown, CT) at 35% amplitude
with a 4-s-on and 2-s-off duty cycle for 1 min. An aqueous phase of 50 μL containing 2 mg
tannic acid was added to the resulting emulsion and sonicated for 50 s, followed by the addition
of 12.5 μL of 40 mg/mL iron chloride water solution with 50 s sonication. The particles were
collected by centrifugation at 135,700 rcf for 15 min, washed with DI water twice, and
lyophilized with a Labconco freeze-dryer (Kansas City, MO).
pTA-P-RRIKA: One milligram of RRIKA dissolved in 50 μL 0.1N HCl was premixed
with 50 μL of 50 mg/mL F127. The mixture was emulsified into 2 mL ultrapure glycerol with
SONICS® Vibra-Cell ultrasonic liquid processor (Newtown, CT) at 35% amplitude with a 4-s-on
and 2-s-off duty cycle for 1 min. Fifty microliters of 0.2M disodium phosphate was added and
sonicated for 50 s using the same parameter settings, followed by the addition of 50 μL of 40
mg/mL tannic acid water solution and 12.5 μL of 40 mg/mL iron chloride water solution. Each
solution was added and sonicated separately for 50 s. Remaining steps were the same as pTARRIKA preparation.
pTA-CaP-RRIKA: The same to pTA-P-RRIKA except for including 50 μL of 0.2M
CaCl2 with sonication post phosphate addition.
pTA-vancomycin: 50 μL of water containing 1 mg vancomycin was premixed with 50 μL
of 0.1N NaOH. The mixture was emulsified into 2 mL ultrapure glycerol with SONICS® Vibra-
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Cell ultrasonic liquid processor (Newtown, CT) at 35% amplitude with a 4-s-on and 2-s-off duty
cycle for 1 min. An aqueous phase of 50 μL containing 2 mg tannic acid was added to the
resulting emulsion and sonicated for 50 s, followed by the addition of 12.5 μL of 40 mg/mL iron
chloride water solution with 50 s sonication. The remaining washing steps followed preparation
of pTA-P-RRIKA.
pTA-P- Polymyxin B: 50 μL of water containing 1 mg polymyxin B was premixed with
50 μL of 50 mg/mL F127, and the mixture was emulsified into 2 mL ultrapure glycerol with
SONICS® Vibra-Cell ultrasonic liquid processor (Newtown, CT) at 35% amplitude with a 4-s-on
and 2-s-off duty cycle for 1 min. The remaining steps were the same as the preparation of pTAP-RRIKA
pTA-CaP-DNA: Premix 50 μL of 5 mg/mL DNA, 50 μL of 0.2M Na2HPO4 and 50 μL of
50 mg/mL F127. The mixture was sonicated into 2 mL ultrapure glycerol with SONICS® VibraCell ultrasonic liquid processor at 35% amplitude with a 4-s-on and 2-s-off duty cycle for 1 min.
Fifty microliters of 0.2M CaCl2, 50 μL of 40 mg/mL tannic acid water solution and 12.5 μL of
40 mg/mL iron chloride water solution were added and sonicated sequentially using the same
sonication parameters. The remaining steps were the same as the preparation of pTA-P-RRIKA.
pTA-DNA was prepared in a similar way except for omitting calcium and phosphate during
preparation.
5.2.3

Characterization of NPs
Particle size and zeta potential was determined by Malvern Zetasizer Nano90

(Worcestershire, UK). The fresh particles before lyophilization was measured in DI water. The
zeta potential was determined at 5 mM pH 7.4 buffer. Particle morphology was observed by
transmission electron microscopy (TEM) without any staining. To determine the drug loading, 1-
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2 mg of pTA-P-RRIKA, pTA-vancomycin or pTA-P-polymyxin B NP was incubated in 0.1N
HCl as 1 mg/mL NP concentration for 30 min. The suspension was centrifuged at 135,700 rcf for
15 min to separate supernatant and was analyzed by HPLC.
5.2.4 Gel electrophoresis
DNA encapsulation in pTA-CaP-DNA NPs was confirmed by 1% agarose gel
electrophoresis with ethidium bromide. The NPs were incubated with 0.1M EDTA (pH 14) for
2.5 h with vigorous stirring to extract DNA. Electrophoresis was performed at 100 V for 30 min
in 0.5×TAE buffer (20mM Tris, 10mM acetic acid and 0.05mM EDTA), and the DNA bands on
gel was imaged by UV at 302 nm through gel documentation system (Azure Biosystems, Dublin,
CA).
5.2.5 HPLC analysis of RRIKA, vancomycin and polymyxin B
HPLC analysis was performed with an Agilent 1100 HPLC system equipped with
Phenomenex Luna 5 μm C18(2) column (100 Å, 250 × 4.6 mm) and UV detector.
Vancomycin: The analysis was detailed in 3.2.5.
RRIKA: The mobile phase was composed of solvent A ((0.05% Trifluoroacetic acid
(TFA) in acetonitrile) and solvent B (0.05% TFA in water) and flowed at 0.7 mL/min. Initially,
the column was equilibrated with a mobile phase consisting of 10% solvent A and 90% solvent B
for 1 min. A linear gradient was then applied, increasing solvent A from 10% to 30% over 4 min.
Subsequently, another gradient was applied, increasing solvent A from 30% to 50% over 10 min.
Then the column was eluted with 50 % solvent A for 2 min, and the mobile phase was returned
to the initial condition and re-equilibrated, making the total analysis time 22 min. RRIKA was
detected at 280 nm.
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Polymyxin B: The mobile phase was a 76:24 (v/v) mixture of 10 mM Na2SO4 pH 2.5 and
acetonitrile, run at a flow rate of 1 mL/min. Polymyxin B was detected at 215 nm.
5.2.6 In vitro drug release
Freeze-dried pTA-P-RRIKA, pTA-Vancomycin and pTA-P-PMB NPs were suspended in
1.11mL of PBS (pH 7.4) or pH 5 acetate buffered saline and incubated at 37°C with constant
agitation for 1 h. The suspension was centrifuged at 135,700 rcf for 15 min at 4 °C to separate
supernatant and pellets. The supernatant was directly analyzed by HPLC and the pellets were
treated with 0.4 mL 0.1N HCl to extract the drug and analyzed by HPLC.

5.3

Results and Discussion

5.3.1 Encapsulation of hydrophilic molecules in pTA nanocapsules encapsulated via quasi
emulsion
Four different hydrophilic molecules were encapsulated in the polymerized tannic acid
nanocapsules via quasi-emulsion method adapted from the inverse emulsion polymerization
method. In inverse emulsion polymerization, a hydrophilic monomer in the aqueous phase is
emulsified into a continuous phase using a W/O emulsifier and polymerized by an initiator [14].
In our study, the aqueous phase containing hydrophilic molecules and a surfactant such as
Pluronic® F127 was dispersed in glycerol as the continuous phase. Due to the high viscosity of
glycerol, the aqueous phase containing hydrophilic drug temporarily formed water droplets in the
glycerol phase under sonication. Subsequently, tannic acid and Fe(III) ions were introduced to
instantaneously form an interfacial layer between the water and glycerol phases through TAFe(III) coordination, stabilizing the droplets and rendering drug-loaded pTA nanocapsules.
We first tested RRIKA (sequence: WLRRIKAWLRRKA), a cationic antimicrobial
peptide effective against planktonic bacteria such as Listeria and Salmonella. According the
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TEM images, pTA-RRIKA nanoparticle showed spherical morphology with a capsule-like
structure (Fig. 45). The average hydrodynamic size of pTA-RRIKA NPs was 349 nm, and the
drug loading capacity was 11.2% (Table 7). NH2HPO4 was coupled with RRIKA to increase
drug retention in NPs via electrostatic interaction between positively charged arginines and
negatively charged phosphates [15]. When 10 mmol Na2HPO4 was supplemented before TA
polymerization to form pTA-P-RRIKA NPs, the drug loading was further increased to 18.0%,
with an average particle size of 454 nm. We also noticed that the RRIKA loading was increased
to 19.5% when 10 mmol Na2HPO4 and 10 mmol CaCl2 were added sequentially before pTA
polymerization. However, with a 50% decrease of Na2HPO4 contents, RRIKA loading was
decreased irrespective of the presence of CaCl2. It implies that sufficient phosphate ions are
critical for high RRIKA loading.

Table 7. RRIKA encapsulation in NPs with different components.

pTA-R
pTA-P-R
pTA-CaP-R
pTA-P-R
pTA-CaP-R

TA
(mg)
2
2
2
2
2

Fe3+
(mg)
0.5
0.5
0.5
0.5
0.5

Ca2+
(mmol)
10
5

H2PO42(mmol)
10
10
5
5

RRIKA
(mg)
1
1
1
1
1

Z-average
(nm)
349 ± 16.5
454 ± 26.0
433.9 ± 33.4
837.1 ± 94.8
607.4 ± 43.0

RRIKA
loading (%)
11.2
18.0 ± 5.2
19.5
10.2
7.7

Polymyxin B, a cationic polypeptide, was encapsulated in the pTA-P carrier in the same
manner (Table 8). The particle size was 422 nm, and the drug loading was 14.3%. Next, we
encapsulated vancomycin in the pTA nanocapsules. Since vancomycin is a neutral glycopeptide
anitbiotic, additional phosphate was not included. pTA-vancomycin NPs had an average particle
size of 246 nm and showed 11.9% vancomycin loading (Table 8). Considering > 10% drug
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loading for all these cases, pTA nanocapsules are promising for encapsulating hydrophilic
molecules.

Table 8.Vancomycin or polymyxin B encapsulation in pTA NPs.

pTA-P-PMB
pTA-vanco

TA
(mg)
2
2

Fe3+
(mg)
0.5
0.5

H2PO42- Vancomycin
(mg)
(mmol)
10
1

Polymyxin
B (mg)

1
-

Z-average
(nm)
422.7 ± 13.4
245.7 ± 3.4

RRIKA
loading (%)
14.3
11.9 ± 0.3

Figure 45. TEM images of drug encapsulating pTA NPs.
5.3.2 Encapsulation of DNA
Cationic polymers like polyethylenimine (PEI) have been widely exploited as carriers for
gene delivery [16]. They condense DNA into small particles by forming an electrostatic
polymer/DNA complex and facilitate cellular uptake by binding to the surface of the cells
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through charge interactions. Also, they can help DNA to escape endolysosomes through ‘protonsponge’ effect and thus reach the nucleus. Nonetheless, their use is hindered by relatively high
cytotoxicity [16]. Co-precipitates composed of calcium phosphate (CaP) and DNA have been
used for > 20 years as gene transfection method in mammalian cell culture [17]. However, when
used alone, CaP-DNA produces colloidally unstable particles and suffer from significant
agglomeration, leading to decreased transfection efficiency [18]. This problem can be
ameliorated by forming TA-Fe(III) complexes on the surface of CaP-DNA co-precipitates, which
will prevent them from further aggregation. Therefore, we encapsulated DNA in the pTA
nanocapsules and integrated CaP to condense DNA in the capsules. The DNA encapsulation was
qualitatively confirmed by gel electrophoresis (Fig. 46). The average particle size of pTA-DNA
was 864 nm, whereas the inclusion of calcium and phosphate (pTA-CaP-DNA) reduced the size
to 550 nm (Table 9).
Table 9. DNA encapsulation in pTA NPs w or w/o CaP.

pTA-DNA
pTA-CaP-DNA

TA
(mg)
2
2

Fe3+
(mg)
0.5
0.5

Ca2+
(mmol)
10

H2PO42(mmol)
10

Salmon DNA

(mg)
0.25
0.25

Z-average (nm)
864.3 ± 233.6
549.5 ± 15.6

Figure 46. DNA identification by 1% agarose gel electrophoresis.
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5.3.3 Drug release from nanocapsules
The drug release from pTA NPs was tested at pH 7.4 and pH 5 buffer, representing
extracellular and intracellular pH values. Less than 20% drug was released from pTA-P-RRIKA
and pTA-P-Polymyxin B NPs, whereas nearly 50% vancomycin was released form pTAvancomycin NPs. This indicates that RRIKA and Polymyxin B were more stably retained in the
NPs than vancomycin, probably due to the complexation with phosphates.

Figure 47. Drug release from pTA NPs at PBS (pH7.4) or pH 5 buffered saline. (a) pTA-PRRIKA. (b) pTA-P-PMB. (c) pTA-vancomycin.
5.4

Conclusion
We have developed a novel particle engineering method for encapsulating hydrophilic

drugs, such as RRIKA, polymyxin B, vancomycin and a model DNA. The hydrophilic drugs are
encapsulated via quasi-emulsion method, where an aqueous phase containing hydrophilic drug
formed transient water droplets in the glycerol phase under sonication due to the dramatic
viscosity difference between glycerol and water. Drug-containing nanocapsules were formed
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with immediate introduction of tannic acid and Fe(III) ions, which form TA-Fe(III) complex at
the interfacial layer between water and glycerol. pTA NPs showed > 10% drug loading in all
tested peptide-based antibiotics with particle sizes ranged from 200 – 600 nm, which indicates
potential utility for therapeutic delivery to phagocytes such as macrophages and dendritic cells.
In the future, hydrophilic antibiotics with smaller molecular weight, such as gentamycin and
amikacin, will be tested for encapsulation, and their structure-encapsulation relationship will be
investigated.
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CONCLUSION

Three different polymeric nanoparticles were engineered to achieve intracellular delivery
of antibiotics to treat intracellular bacterial infection. Initially, Zwitterionic chitosan (ZWC) with
a pH-dependent charge profile was synthesized as a carrier of CAMPs to the intracellular
pathogens. ZWC formed complex with two candidate CAMPs (WR12 and RRIKA) at
physiological pH and dissociated at lysosomal pH; however, the complex was not stable in the
presence of ions and proteins, limiting the systemic application of this system. To enhance the
stability, ZWC/WR12 complex was encapsulated in PLGA (PZW) NP. Although the stability
was enhanced, they were not effective against intracellular bacteria in macrophages due to the
lack of drug release at lysosomal pH. Therefore, ZWC was replaced by another pH-sensitive
material, acid-soluble polymethacrylate Eudragit E100. When encapsulated in the PEW NPs, no
WR12 was observed at pH7.4, whereas significant release was observed at pH 5. However, due
to the toxicity resulting from intracellularly released E100 and WR12, PEW NPs were no longer
pursued, and the antibiotic was replaced with vancomycin. Despite the undesirable biological
outcomes, this study delivered two meaningful messages: (i) ZWC and E100 were potential pHsensitive materials for facilitating drug release at acidic pH; (ii) When molecules with inherent
limitation in cellular uptake enter cells with the aid of carriers, they may exhibit unique
cytotoxicity profiles.
Recognizing ZWC and E100 as promising pH-sensitive materials, we encapsulated
vancomycin in a particle formulation (PpZEV) based on a blend of polymers with distinct
functions: (i) PLGA (P) serving as the main delivery platform, (ii) PEG-PLGA (p) to help
maintain an appropriate level of polarity for timely release of vancomycin, (iii) Eudragit E100
(E) to enhance vancomycin encapsulation, and (iv) ZWC (Z) to trigger pH-sensitive drug release.
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PpZEV NPs were preferentially taken up by the macrophages due to its size (500-1000 nm) and
facilitated vancomycin delivery to the intracellular pathogens. Accordingly, PpZEV NPs showed
better antimicrobial activity than free vancomycin against intracellular MRSA and other
intracellular pathogens in vitro. However, the burst drug release at physiological pH was
concerning for in vivo application because it could indicate premature drug loss before arrival at
the target. To avoid this, PpZEV NPs were optimized with respect to circulation stability and
drug loading capacity by titrating ZWC and vancomycin feed in the formulation. The optimized
PpZEV NPs (opt-PpZEV NPs) were superior to free vancomycin in killing MRSA loads in the
liver and spleen due to its fast accumulation in these organs, specifically facilitating vancomycin
delivery to the macrophages where the intracellular bacteria predominantly resided. This
indicates that opt-PpZEV NPs are promising for treating intracellular MRSA. No toxicity was
indicated from the opt-PpZEV according to body weight measurement and gross observation of
organs. However, given the known toxicity of E100, more detailed toxicity studies such as blood
chemistry and histology will need to be performed.
Lastly, we developed a simple, cost-effective and eco-friendly particle engineering
method for encapsulating hydrophilic antibiotics, such as RRIKA, polymyxin B and
vancomycin, in tannic acid nanocapsules via quasi-emulsion method. In short, aqueous phase
containing a hydrophilic drug formed transient water droplets in the glycerol phase under
sonication because of the viscosity difference between glycerol and water. Upon introduction of
tannic acid and Fe(III) ions, drug encapsulating pTA NPs were formed due to the formation of
TA-Fe(III) complex at the interfacial layer between water and glycerol. To enhance drug
loading, Na2HPO4 were coupled with cationic antibiotics before pTA formation. In all tested
peptide-based antibiotics, pTA NPs showed > 10% drug loading with particle sizes ranged from
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200 – 600 nm, indicating potential utility for intracellular delivery to phagocytes such as
macrophages and dendritic cells. In the future, non-peptide-based antibiotics such as gentamicin
and amikacin will be encapsulated, and the NPs will be characterized in terms of particle size,
drug encapsulation, surface charge, particle morphology, and drug release. We will compare the
results from different antibiotics to understand the potential structure-encapsulation relationship.
In addition, the toxicity of the carrier as well as their intracellular antimicrobial activity will be
tested in bacteria-resident macrophages.
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